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1. INTRODUCTION 
 
During last decades HIV infection has become one of the main problems of 
infectious diseases and presents a major challenge to the medicine worldwide. 
From the beginning of the HIV epidemic about 60 million subjects have been 
infected and 25 million have died. In 2009 it was estimated that 3135 million 
persons live with HIV infection. Every year about 2.6 million new HIV 
infections and 1.8 million AIDS deaths are reported (www.who.int). 
The AIDS and its causative agent HIV are relatively new. Recent studies 
suggest that virus started to spread in wider scale not before 1940s (Korber, 
Muldoon et al. 2000). However, it took more than 40 years when the AIDS was 
noticed and the syndrome causing virus got identified. Discovery of this virus 
had been awarded with the Nobel price in Medicine in 2009 which again refers 
that the management of HIV epidemics is one of the most important challenges 
in contemporary medicine and science.  
For a long time HIV infection was untreatable slowly progressing to the 
death in about 7 years. The first treatments emerged in the 1980s but the real 
breakthrough was in 1995 when the first effective antiretroviral treatment  
HAART was initiated. Today the HIV infection in countries with full access to 
medical care is life-long chronic disease which allows life-expectancy 
comparable to non-infected persons (Bhaskaran, Hamouda et al. 2008). 
Unfortunately so far many drawbacks and questions are still associated with 
treatment of HIV infection. Firstly, there is a need for complex and well 
managed ARV therapy because of the rapidly developing drug resistance. 
Secondly, the emerging TDR compromises the choice of first line treatment 
among TN patients. Thirdly, the impact of the natural variability of HIV to the 
efficiency and outcome of HAART is not well described. These are the main 
questions of the worldwide scientific and medical community to be resolved 
before a full control over the HIV epidemic is achieved.  
For Estonia, a country with the highest HIV-1 prevalence and incidence in 
Europe, the HIV epidemic possesses additional socio-economical hurdles, espe-
cially as the infected population consists of various minorities including 
Russian speaking immigrants and IVDUs community (Estonian Health Board, 
Tallinn, 2010 (cited 2010 February 16). Accessed at www.terviseamet.ee). In 
terms of HIV-1 epidemic Estonia is a country belonging to “new Eastern-
European” HIV-1 epidemics. Compared to Western-Europe the knowledge 
about the HIV-1 molecular epidemiology and DR in Eastern-Europe and 
especially in Estonia is limited. Futhermore the evolving of the epidemic forces 
to pay more attention to the generaliation of epidemics, to its consequences of 
scaling-up the HAART and to the outcome of the disease caused by under-
investigated non-B type viruses. 
 
 
 
 11
2. REVIEW OF LITERATURE 
 
2.1 HIV-1 genomic structure and  
molecular epidemiology 
 
HIV-1 is a retrovirus belonging to the family of lentiviruses (Lentiviridae). Its 
provirus is approximately 9800 nt in length (Muesing, Smith et al. 1985). 
 
 
2.1.1 Genome structure 
 
Similar to other retroviruses HIV-1 genome consists of central protein coding 
region which has both ends flanked by the LTR. Proteins encoded by HIV-1 are 
divided into major structural, regulatory and accessory proteins as shown in 
Figure 1 (Gallo, Wong-Staal et al. 1988).  
 
Figure 1. Structure of HIV-1 genome. 
 
 
2.1.1.1 Long terminal repeats 
  
LTRs are composed of three regions  U3, R and U5 (Starcich, Ratner et al. 
1985; Hope and Trono 2000). 
 U3 region consists of cellular transcripton factor binding sites 
 R region starts with the transcriptional start site and ends with the mRNA 
polyadenylation sites   
 U5 contains Tat binding site, packing signals for HIV-1 genomic RNA and 
lysyl-tRNA binding site. The lysyl-tRNA is a primer for the reverse 
transcription.  
 
 
2.1.1.2 Major functional proteins 
 
The HIV-1 possesses three major functional proteins. The gag protein is 
structural unit of the viral capsid. Gag contains the binding sites for viral 
genomic RNA and is responsible for incorporation of viral RNA into the capsid. 
Gag protein initiates the budding of viral particle from the cellular surface. 
Inside of the viral particle the gag polyprotein is cleaved to mature matrix, 
capsid and nucleocapsid proteins by viral PRs (Gottlinger, Sodroski et al. 1989). 
The pol region of viral genome is always expressed as gag-pol fusion 
polyprotein as a consequence of ribosomal frame shift during the translation of 
 12
gag protein (Jacks, Power et al. 1988). Thereafter polyprotein is processed by 
viral PR to following functionally active viral enzymes: PR, RT, RNase H and 
IN (Hope and Trono 2000).   
 PR – HIV-1 PR is a 99 aa long aspartyl PR which is active in dimeric form 
(Miller, Jaskolski et al. 1989). It is responsible for maturation of gag and 
gag-pol precursor polyproteins (Schneider and Kent 1988). Contrary to 
classic proteases it does not have consensus target sequence but it recognizes 
the specific asymmetric shape in substrate peptide sequences (Prabu-
Jeyabalan, Nalivaika et al. 2002).  
 RT – is a 440 aa protein having a RNA- and DNA dependent DNA 
polymerase activity. It is responsible for reverse transcription of viral RNA 
to DNA and incorporation with RNase H for the synthesis of the second 
chain of this DNA. Similarly to PR the RT active form is a dimer consisting 
of p65 and p50 subunits (p50 is active subunit consisting of RT sequence; 
p65 is inactive subunit consisting of RT and RNase H fusion sequences). 
The HIV-1 RT lacks proofreading activity causing its error-prone nature and 
therefore high intra- and interindividual viral sequence diversity (Roberts, 
Bebenek et al. 1988; Wensing, van de Vijver et al. 2005). In combination 
with high recombination rate and short half-life of HIV-1 particles this 
allows rapid selection of immune system escape as well as DRMs (Ho, 
Neumann et al. 1995; Michael 1999; Rollman, Hinkula et al. 2004).    
 IN – is a 288 aa protein which is responsible for integration of viral genomic 
DNA into host chromosome. IN possesses at least three distinct functions – 
exonuclease activity for trimming viral genomic DNA, endonuclease activity 
for cleaving host genomic DNA for proviral integration and ligase activity 
for single stranded ligation of viral and host DNA (Bushman, Fujiwara et al. 
1990).  
 RNase H main function is the degradation of viral RNA in DNA:RNA 
duplex during the reverse transcription (Hope and Trono 2000).   
endoplasmatic reticulum and glycosylated in several aspartate residues. There-
after it is cleaved to gp41 and gp120 proteins which, however, remain linked 
with non-covalent interaction. Such complex forms a homo-trimer that is 
responsible for HIV-1 binding and fusion to target cell (Bushman, Fujiwara et 
al. 1990). Functionally the gp120 is responsible for interactions between HIV-1 
cellular receptor CD4 and cellular co-receptors CCR5 or CXCR4 (Landau, 
Warton et al. 1988; Hope and Trono 2000).  
 
 
2.1.1.3 Regulatory proteins 
 
HIV-1 has two regulatory proteins tat and rev. Tat is RNA binding protein 
activating transcription in 5´viral RNA terminus by binding to transactivation 
response element in LTR. It promotes the transcriptional elongation of HIV-1 
RNA. Tat interacts with many cellular proteins to influence the expression of 
The env is approximately 500 aa long fusion protein, which is translated into 
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several host genes. The second regulatory protein rev binds to viral RNA 
regulating the transition from early to late phase of HIV-1 gene expression 
(Kim, Byrn et al. 1989; Hope and Trono 2000).  
 
 
2.1.1.4 Accessory proteins 
 
HIV-1 has four accessory proteins – nef, vif, vpr and vpu. These proteins are 
not essential for in vitro replication but act as virulence factors in vivo. Most of 
these proteins have multiple functions. Nef downregulates the CD4 and MHC 
Class I molecule expression and modulates the T-cell activation (Roeth and 
Collins 2006). Vif is required in HIV-1 replication in PBMCs but not in other 
cell types (Gabuzda, Lawrence et al. 1992). Vpr is incorporated into viral 
particle and facilitates the nuclear transport of preintegration complex and 
modulates the cell cycle regulation (Romani and Engelbrecht 2009). Vpu is 
integral membrane phosphoprotein, which downregulates the CD4 and 
enhances the virion release from the cell surface (Schubert, Bour et al. 1996). 
Vpu releases the env protein from CD4+ cells in endoplamatic reticulum 
allowing the effective budding of new viral particles (Willey, Maldarelli et al. 
1992). 
 
 
2.1.2 HIV-1 taxonomy and phylogenetic distribution 
 
The HIV in humans is diverse class of viruses. Phylogenetic analysis of similar 
viruses in other primates has demonstrated multiple-cross species transmissions 
of these viruses to human populations (Figure 2) (Buonaguro, Tornesello et al. 
2007).  
The HIV-1 is divided into three groups  M (major), O (outlier) and N (non-
M/non-O) (Figure 2). It seems that these groups are not monophyletic and most 
probably originate from the strains of simian immunodeficiency viruses 
(SIVCPZ) found in chimpanzees Pan troglodytes troglodytes in West-Equatorial 
Africa (Gao, Bailes et al. 1999). The most divergent set of HIV-1 taxons in the 
world have been described in that particular area. (Janssens, Nkengasong et al. 
1994; Delaporte, Janssens et al. 1996; Peeters, Gaye et al. 1996; Vidal, Peeters 
et al. 2000; Mokili, Rogers et al. 2002; Buonaguro, Tornesello et al. 2007). 
Recently the HIV-1 group P has also been found in one Cameroonian woman, 
however, contrary to other HIV-1 groups this virus possesses the closest relative 
to gorilla simian immunodeficiency viruses (Figure 2) (Plantier, Leoz et al. 
2009). 
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Figure 2. Phylogenetic tree representing HIV-1 group M, N, O and P and related SIV 
sequences. Figure is adapted from (Plantier, Leoz et al. 2009). 
 
 
From these HIV-1 groups the M-group has by far the greatest clinical impor-
tance and it also demonstrates the largest sequence diversity. Group M is 
divided into 9 subtypes (A, B, C, D, F, G, H, J and K) and tens of recombinant 
forms (www.hiv.lanl.gov/content). The latter in turn are divided into CRFs and 
URFs. The CRFs are defined as viral strains which have been isolated from at 
least two epidemiologically unrelated persons, whereas URFs are viruses 
described only in one person or epidemiologically related persons (Robertson, 
Anderson et al. 2000). The largest abundance of different CRFs and URFs have 
been described in Central-Africa, in the region where several HIV-1 clades co-
circulate (Konings, Haman et al. 2006). The recombinant forms have also been 
found between different HIV-1 groups and in single cases even between HIV-1 
and HIV-2 strains (Butler, Pandrea et al. 2007; Yamaguchi, Vallari et al. 2008).  
Recent detailed phylogenetic analysis of HIV-1 group M viruses showed that 
subtypes A and F can be further separated into sub-subtypes: A1, A2, A3 and 
F1, F2. Their phylogenetic diversity is comparable to that in other subtypes. In 
phylogenetical terms these viruses should be considered as independent 
subtypes (Triques, Bourgeois et al. 2000; Gao, Vidal et al. 2001; Ojesina, 
Sankale et al. 2006). On the contrary the HIV-1 subtypes B and D are 
phylogenetically so similar that they could be regarded as one subtype (Triques, 
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Bourgeois et al. 1999; Triques, Bourgeois et al. 2000; Gao, Vidal et al. 2001; 
McGrath, Hoffman et al. 2001; van der Auwera, Janssens et al. 2001).  
The most prevalent HIV-1 subtype worldwide is subtype C causing approxi-
mately 50% of all infections (Buonaguro, Tornesello et al. 2007). It is spread 
mainly in Southern–African countries and India. In terms of frequency it is 
followed by the subtypes A and B, the former dominating in Central- and 
Eastern-Africa as well as in Eastern-Europe and the latter in Western- and 
Central-Europe, North- and South-America, Australia and several South-East-
Asian and Northern-African countries (Figure 3). Other subtypes like F, G, H, J 
and K demonstrate much restricted spread and are localized mainly in Central-
Africa. CRFs account for approximately 18% of all HIV-1 infections (Osma-
nov, Pattou et al. 2002; Hemelaar, Gouws et al. 2006). The most widespread of 
them are CRF01_AE and CRF02_AG spreading predominantly in South-East 
Asia and West-Africa, respectively (Osmanov, Pattou et al. 2002). 
 
 
 
Figure 3. Distribution of HIV-1 subtypes and CRFs in the world. White represents 
areas with insufficient data. 
 
 
The most predominant subtype in North-America and Western-Europe is sub-
type B. The phylogenetic analysis indicates that these viruses have mono-
phyletic origin dating back to 1960s in Haiti (Gilbert, Rambaut et al. 2007). 
Western-European viruses, however, do not form a single cluster of Western-
World subtype B viruses suggesting that several independent introductions from 
USA or from Haiti have occurred (Paraskevis, Pybus et al. 2009).  
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Other HIV-1 subtypes have been spread in Western-Europe in lower extent. 
For example, the relatively high prevalence of HIV-1 subtype G viruses has 
been described in Portugal only (Esteves, Parreira et al. 2003).  
However, during last decade many studies have demonstrated the increasing 
prevalence of non-B subtypes in Western-Europe mainly among those with 
potential of acquiring infection abroad (eg. recent immigrants from Africa) 
(Deroo, Robert et al. 2002; Chaix, Descamps et al. 2003; Snoeck, van Laethem 
et al. 2004; Descamps, Chaix et al. 2005; Lospitao, Alvarez et al. 2005).  
In Estonia first cases of HIV-1 infection were reported in 1988 but the 
incidence (9 per million inhabitant in 1999) of it remained low until 2000. The 
main route of infection at that time was homo- or heterosexual transmission 
(Ustina, Zilmer et al. 2001; Laisaar, Avi et al. 2011). The molecular epi-
demiological studies have confirmed that the subtype distribution was similar to 
that seen in Western–Europe – unrelated subtype B viruses accompanied by a 
few cases of A, C, D, G and CRF02_AG subtypes (Liitsola, Laukkanen et al. 
1996; Ustina, Zilmer et al. 2001). 
In the early 1990s after the collapse of Soviet Union and together with the 
rapid increase of intravenous drug use the concentrated HIV-1 epidemics 
emerged in the Southern Ukraine, spreading rapidly to neighboring countries 
like Belarus and Russia (Bobkov, Cheingsong-Popov et al. 1997; Lukashov, 
Karamov et al. 1998; Nabatov, Kravchenko et al. 2002; Naganawa, Sato et al. 
2002). By 1999 the expanding Eastern-European HIV-1 epidemic had reached 
to the surrounding regions of Estonia  Latvia and St. Petersburg area in Russia. 
Vast majority of infections were caused by monophyletic subtype A1 viruses 
(Bobkov, Cheingsong-Popov et al. 1997; Roudinskii, Sukhanova et al. 2004). In 
lesser extent the HIV positive subjects, mainly in the region of Kaliningrad 
oblast and Ukraine, were also infected by the new recombinant form 
CRF03_AB originating from the same subtype A1 and subtype B (Liitsola, 
Holm et al. 2000; Naganawa, Sato et al. 2002). Among these Eastern-European 
subtype A1 viruses the sub cluster labelled with protease mutation V77I was 
also described (Roudinskii, Sukhanova et al. 2004; Vazquez de Parga, Rakhma-
nova et al. 2005; Zarandia, Tsertsvadze et al. 2006). 
In Estonia the concentrated HIV-1 epidemic burst in August 2000 when the 
number of HIV-1 infected subjects arose rapidly reaching the highest pre-
valence (1053 per million inhabitants) in European Union in 2001 (Uuskula, 
Kalikova et al. 2002). Since then the incidence has been gradually decreasing 
and was 307 per million inhabitants in 2009. Still Estonia is one of the three 
countries in Eastern-Europe and Central-Asia in which the estimated HIV-1 
prevalence exceeds 1% of adult population (www.unaids.org). In contrast to 
population infected with HIV-1 prior to 2000 (eg. mainly hetero- or homo-
sexually infected middle-aged persons) over two-thirds of affected subjects 
were male IVDUs under the age of 30 (Figure 4) (Estonian Health Board, 
Tallinn, 2010 (cited 2010 February 16). Accessed at www.terviseamet.ee) 
(Lõhmus, Rüütel et al. 2002; Talu, Abel-Ollo et al. 2008). 
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Figure 4. Newly diagnosed HIV-1 cases per million in Estonia 2000-2010. Blue 
squares indicate men, red squares indicate women (Estonian Health Board, Tallinn, 
2010 (cited 2010 February 16). Accessed at www.terviseamet.ee; Statistics Estonia, 
Tallinn, 2010 (cited 2010 January 5, July 5, and Nov 8). Accessed at www.stat.ee). 
 
 
Surprisingly and in contrast to other former Soviet Union countries the Estonian 
HIV-1 epidemic was not caused by the subtype A1 but it was predominated by 
the rare HIV-1 CRF06_cpx and in lesser extent by its recombinants with the 
subtype A1 (Zetterberg, Ustina et al. 2004; Adojaan, Kivisild et al. 2005).  
The HIV-1 CRF06_cpx was first described in 1998-1999 in Mali and 
Burkina Faso as a CRF formed by subtypes A, G, K and J (Figure 5A) 
(Oelrichs, Workman et al. 1998; Montavon, Bibollet-Ruche et al. 1999; Triques, 
Bourgeois et al. 2000; Montavon, Toure-Kane et al. 2002). Prior to the  
Estonian outbreak the CRF06_cpx was spreading mainly in Mali, Niger and 
Burkina Faso and only single strains had been described outside of Africa 
(Oelrichs, Workman et al. 1998; Montavon, Bibollet-Ruche et al. 1999; Mama-
dou, Montavon et al. 2002; Montavon, Toure-Kane et al. 2002; Mamadou, 
Vidal et al. 2003). 
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Figure 5. The structure of HIV-1 CRF06_cpx (panel A) and CRF32_06A1 (panel B). In 
panel A the strain contains sequences from subtypes A, G, K, J and of unknown origin 
(marked as white) and in panle B from CRF06_cpx and in lesser extent from subtype 
A1 (www.hiv.lanl.gov).   
 
 
In early 2000 the Estonian HIV-1 epidemic was highly homogeneous  approxi-
mately 70% of infections were caused by the monophyletic CRF06_cpx strains 
containing highly similar or even identical sequences (Zetterberg, Ustina et al. 
2004; Adojaan, Kivisild et al. 2005). This suggests the possibility of one source 
origin of Estonian HIV-1 epidemic. Still, about  fifth of the viral strains were 
the second generation recombinants between CRF06_cpx and Eastern-European 
subtype A1 viruses designated also as CRF32_06A1 (Figure 5B) (Zetterberg, 
Ustina et al. 2004; Adojaan, Kivisild et al. 2005). Deeper analysis of these 
strains revealed a number of different URFs suggesting the high rate of 
superinfections in Estonian IVDU population (Zetterberg, Ustina et al. 2004; 
Adojaan, Kivisild et al. 2005). Furthermore, in rare cases the pure subtype A1 
sequences as well as subtype B sequences have also been described (Zetterberg, 
Ustina et al. 2004; Adojaan, Kivisild et al. 2005). 
 
2.2 Antiretroviral agents and HAART 
 
The first ARV therapy was used in late 1980s when ZDV monotherapy was 
given. As a results of treatment the reduction in the incidence of opportunistic 
infections, increase in the CD4+ cell count and decrease of mortality was 
observed (Fischl, Richman et al. 1987; Volberding, Lagakos et al. 1990). Un-
fortunately due to the emerging resistance to ZDV the long term clinical 
outcome after monotherapy was not different of that seen in the placebo group 
(Concorde-Coordinating-Committee 1994). Therefore since early 1990s the 
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ZDV monotherapy was recommended only for patients with advanced disease 
(Concorde-Coordinating-Committee 1994; Volberding, Lagakos et al. 1995).  
The greatest breakthrough in the treatment of HIV-1 infection was achieved 
in mid-1990s with the introduction of triple ARV therapy called HAART. This 
was made possible due to the discovery and introduction of two new classes of 
ARV agents  the PIs (SQV, RTV, IDV) and NNRTIs (NVP). New triple 
therapy combining the dual NRTI backbone with a PI demonstrated during 
treatment a remarkable increase of time to AIDS defining events and death 
(Hammer, Squires et al. 1997). For example, the introduction of HAART 
resulted about two fold decrease in new cases of AIDS and about three fold 
decrease in mortality within 4 years (Fleming, Ward et al. 1998; Murphy, 
Collier et al. 2001).  
The usage of PIs also led to the introduction of boosted PI regimen  a low 
dose RTV was added to other PI-containing regimens. This in turn improved the 
treatment outcome by increasing the time left until the development of AIDS 
and death. This boosting mechanism was caused by the RTV ability to inhibit 
cytochrome P450 CYP 3A4 enzyme which results in the increase of drug’s 
blood concentration and gives greater antiviral effect compared to unboosted 
PIs (Kempf, Marsh et al. 1997; Walmsley, Bernstein et al. 2002). In initial stu-
dies such regimen practically did not select out any DRMs which had become 
the main obstacle of long-term ARV therapy (Walmsley, Bernstein et al. 2002).  
Despite successful HAART the growing number of ARV agents, the number 
of patients undergoing ARV treatment, especially in low income countries, and 
the prolonged periods during which patients have taken these substances has 
drawn our attention to the toxicities and the emergence of drug resistance to 
ARV agents. To overcome these problems new ARV classes CCR5 antagonists, 
integrase inhibitors and next generation PIs and NNRTI have been developed 
recently (De Clercq 2010). 
 
 
2.2.1 ARV classes 
 
By the year 2010 a total of 25 ARV agents consisting of 8 NRTIs, 4 NNRTIs, 
10 PIs, 1 FI, 1 INI and 1 CCR5 receptor antagonist have been approved in US 
and in Europe (Table 1).  
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Table 1. ARV drugs approved by the Food and Drug Administration and by European 
Medicines Agency 
 
NRTI  PI  
abacavir ABC amprenavir APV 
didanosine ddI atazanavir ATV 
emtricitabine FTC darunavir DRV 
lamivudine 3TC fosamprenavir FPV 
stavudine d4T indinavir IDV 
tenofovir TDF lopinavir LPV 
zalcitabine ddC nelfinavir NFV 
zidovudine ZDV or AZT ritonavir RTV 
NNRTI  saquinavir SQV 
delavirdine DLV tipranavir TPV 
efavirenz EFV FI  
etravirine ETR enfuvirtide ENF 
nevirapine NVP CCR5 inhibitors  
INI  maraviroc MVC 
raltegravir RAL   
 
 
2.2.1.1 Nucleotide/nucleoside reverse transcriptase inhibitors 
 
NRTIs are nucleoside or nucleotide analogues which compete with the natural 
nucleotides for the incorporation to newly synthesized DNA. In case of 
incorporation into the proviral DNA they cause nucleotide chain termination 
and prevent further replication process (Shafer 2004).  
All 7 NRTIs (Table 1) are pro-drugs which need phosphorylation for the 
activation. However, the different activity of intracellular kinases and expres-
sion of uptake transporters the intracellular concentration of triphosphorylated 
NRTI methabolites may greatly vary between cell types causing significant 
intra- and interindividual variability resulting in different inhibiting potential of 
these ARV drugs (Shafer 2002).  
 
 
2.2.1.2 Non-nucleoside reverse transcriptase inhibitors 
 
Contrary to NRTI, NNRTIs act as non-competitive RT inhibitors. Despite their 
diverse chemical structure they bind to the same small hydrophobic pocket near 
the active site of RT (Ghosn, Chaix et al. 2009). NNRTIs are able to inhibit 
only the HIV-1 group M viruses having no impact to the HIV-2 or HIV-1 group 
O (Witvrouw, Pannecouque et al. 1999; Shafer 2004). The first generation 
NNRTIs (DLV, EFV, NVP) are tightly fixed into the hydrophobic pocket of 
RT. Such interaction can be easily broken by the emergence of one DRM which 
makes the first generation NNRTIs of low genetic barrier drugs. In contrast, the 
second generation NNRTIs (ETR) are designed with more flexible chemical 
structure allowing several conformations within the hydrophobic pocket and 
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therefore require emergence of several DRMs before the agent loses its affinity 
to NNRTIs (Ghosn, Chaix et al. 2009). 
 
 
2.2.1.3 Protease inhibitors 
 
PIs are molecules which bind to HIV-1 PR with high affinity occupying larger 
space than enzyme natural substrate (polypeptide chain) itself. At the beginning 
of the PI usage many of these drugs had major problems with their bio-
availability causing high bill burdens, low adherence and limited long term viral 
inhibition, therefore leading to the emergence of DRMs (van Heeswijk, Veld-
kamp et al. 2001). The change in PI efficiency took place due to the intro-
duction of low dosage RTV as a pharmacokinetic booster as described before. 
Today almost all PIs have been administered with low-dose ritonavir.   
 
 
2.2.1.4 Integrase inhibitors 
 
The INIs block the HIV-1 integration complex insertion to the host cell genome. 
Lack of cross-resistance with other so far widely used PR and RT inhibitors has 
made it an essential component of ARV regimens against highly resistant 
viruses (Powderly 2010). A considerable advantage is also INI’s potential of 
low toxicity comparing to other first line HAART components (Powderly 
2010).  
 
2.2.1.5 Entry inhibitors 
 
Entry inhibitors are divided into two classes: CCR5 antagonists and fusion 
inhibitors. CCR5 antagonists bind to HIV-1 co-receptor CCR5 blocking the R5 
tropic virus binding to its co-receptor and thus preventing the viral entry into the 
target cells (Pierson, Doms et al. 2004). The fusion inhibitors are short peptides 
consisting of aa sequences similar to HIV-1 env transmembrane C-terminal 
heptat repeat region (gp41). These drugs prevent the formation of a complex 
between gp41 N-terminal and C-terminal hepta-repeat regions required for the 
viral and host cell membrane fusion (Makinson and Reynes 2009). Albeit 
having closely related targets these two drugs have distinct DRM profiles 
(Shafer and Schapiro 2008).  
 
 
2.2.2 HIV-1 DRM and their testing 
 
The HIV-1 DRM can be tested by using genotypic and phenotypic assays. The 
genotypic assays determine the ARV DRMs in the viral nucleic acid sequences 
and interpret them according to previously composed algorithms (Shafer 2002). 
Phenotypic assays determine the DR directly measuring the viral replication in 
cell cultures in the presence of different consentration of ARV agents. The 
sensitivity of HIV-1 drug resistance tests compared to viral quantification 
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assays is approximately 20 times lower (25–50 copy/μl vs. 1000 copy/μl) as the 
drug resistance tests generally amplify about ten times longer viral genomic 
region (Shafer 2002). 
In clinical practice the genotypic assays are more widely used than pheno-
typic assays because of their lower price, wider accessibility and shorter run-out 
time. The advantages of genotypic assays over phenotypic assays involve their 
ability to detect mutations from viral mixtures up to 20% of populations and 
transition mutations referring to archived drug resistance (Meynard, Vray et al. 
2002; Shafer 2002). Phenotypic assays are mainly used for the evaluation of the 
new DRMs and for the determination of DR for heavily treated patients (Shafer 
2002). 
Both these assays are able to determine the DR only in actively replicating 
viruses and not in the viruses archived in the resting T-cells or other tissues. 
Therefore these tests represent the viral resistance only against the recent ARV 
therapies (Kozal, Shafer et al. 1993; Koch, Yahi et al. 1999).  
 
 
2.2.2.1 Genotypic drug resistance assays 
 
The workflow of the genotypic assays generally begins with the viral RNA 
extraction, its reverse transcription to cDNA, amplification by PCR and Sanger 
sequencing in ARV target regions like PR, RT and recently also in IN and env 
ViroSeq version 2.0 HIV-1 Genotyping System (Abbott Laboratories, USA), 
Truegene HIV genotyping system (Bayer Health Care LLC, USA), (Lindstrom 
and Albert 2003; Steegen, Demecheleer et al. 2006; Grant and Zolopa 2008; He, 
Cheng et al. 2008; Paar, Palmetshofer et al. 2008; Saravanan, Vidya et al. 
2009). Genotypics assay generally sequences almost entire PR and the 5´part of 
the RT (first 240 aa) region where the majority of DRMs are located. Acquired 
sequences are assembled and compared with subtype B reference sequences for 
the detection and interpretation of DRMs using different algorithms (see 
2. . .2). The Sanger sequencing is the population sequencing which is able to 
detect indicates the DRMs for the most abundant quasispecies of the currently 
replicating viruses in blood.  
Genotypic drug resistance testing can be conducted by commercial kits 
(commercial HIV-1 DR assays) or by protocols developed in non-commercial 
labs (so called in house assays). Recent study has indicated the high concor-
dance between these two approaches (Saravanan, Vidya et al. 2009). 
 
 
2.2.2.2 Genotypic test results 
 
The genotypic test generates a list of mutations which has been associated with 
HIV-1 ARV DR in earlier studies. Based on these mutations the interpretation 
algorithms are used to calculate the viral susceptibility to different ARV agents 
most often by computerized expert systems. The independence of DR deter-
mination from the interpretation process makes possible the usage of different 
2 2
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interpretation systems on the same sequence information. The most commonly 
used list of DRMs, HIV-1 genotypic interpretation algorithms and interactive 
interpretation systems are as follows: Stanford University HIV Drug Resistance 
Database (hivdb.stanford.edu), ANRS drug resistance interpretation algorithm 
(www.hivfrenchresistance.org), Rega Institute Drug Resistance Interpretation 
Algorithm (www.rega.kuleuven.be) and International AIDS Society–USA drug 
resistance mutations list (www.iasusa.org) (van Laethem, De Luca et al. 2002).  
 
 
2.2.2.3 Virtual phenotype 
 
Alternative way to interpret HIV-1 DR sequence information is to use virtual 
phenotype. It is a commercial algorithm which uses large genotype-phenotype 
relation database, linking the query sequence to most similar DRM pattern 
possessing database entries. The corresponding database entry susceptibilities to 
different ARVs have been considered to calculate the clinical result about this 
query DR profile (Verbiest, Peeters et al. 2000; Shafer 2002). 
 
 
2.2.2.4 Phenotypic resistance tests 
 
In classical phenotypic assays the virus is isolated and cultivated for 10-14 days 
on healthy individuals PBMCs. This makes this test expensive and time con-
suming. On the contrary, modern commercial phenotypic assays reverse 
transcribe and amplify viral PR-RT regions and insert them to viral vectors. It 
allows to avoid the first viral replication in PBMCs, which increases the assay 
sensitivity and lowers the cost. In both cases the viruses or viral constructs’ 
fitnesses have been compared to reference strains in cell culture conditions in 
the presence of different ARV drugs. The results have been reported as 
concentration of ARV agents which inhibit the viral replication by 50% or 90% 
(expressed as IC50 or IC90).  
Recently clinical assays which determine the viral tropism to CCR5 or to 
CXCR4 expressing cells have also been introduced. The most widely used is a 
commercial Trofile co-receptor tropism assay (www.trofileassay.com). At the 
first stage it resembles other phenotypic assays consisting of target region (env) 
reverse transcription, amplification and insertion to viral vector lacking the env 
region. Finally the replication ability of the constructs will be tested on CCR5 
or CXCR4 expressing cell lines.  
 
 
2.2.3 Drug resistance mutations 
 
According to mechanisms the HIV-1 DRMs can be divided into two cate-
gories – primary and secondary DRMs. The emergence of primary DRMs cause 
direct resistance to certain ARV agents and increases the viral load in vivo. As a 
cost of the emergence of these mutations viruses loose their replication fitness 
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compared to wild type viruses. The replication fitness can be restored by the 
emergence of other compensatory or secondary DRMs. Secondary DRMs 
usually do not cause DR, their impact to viral fitness emerges only together 
with primary mutations.  
 
 
2.2.3.1 NRTI drug resistance mutations 
 
NRTI mutations are divided into M184V, TAM, mutations selected by regi-
mens lacking thymidine analogues (non-TAM), multi–nucleoside resistance 
mutations and non-polymorphic accessory mutations (Shafer and Schapiro 
2008). According to resistance mechanism NRTI DRMs can be divided into 
two classes. The first one decreases the frequency of incorporation of NRTIs 
into viral genomic DNA and includes mutations M184V, non-TAMs K65R and 
L74V and multi–nucleoside resistance mutation Q151M (Deval, Selmi et al. 
2002; Deval, White et al. 2004). The second mechanism removes once in-
corporated NRTIs from the growing polynucleotide chain thus leading to primer 
unblocking and includes TAMs, T69 insertions and many accessory mutations 
(Arion, Kaushik et al. 1998; Boyer, Sarafianos et al. 2001). 
The most abundant NRTI mutation is M184V causing high level resistance 
to most common first line ARV agents like 3TC, FTC and low level resistance 
to ddI, ABC, and increases susceptibility to ZDV, d4T, TDF (Whitcomb, Parkin 
et al. 2003). The M184V is frequently accompanied by the mutation K65R and 
L74V (Moyle, DeJesus et al. 2005; Eron, Yeni et al. 2006; Gallant, DeJesus et 
al. 2006; Shafer and Schapiro 2008). Less common mutations occurring during 
virologic failure under the non-TA regimens are K65N, K70EG and Y115F 
(Shafer and Schapiro 2008).  
TAMs have been selected by the thymidine analogues and are causing 
resistance to ZDV and d4T but in lesser extent also to ABC, ddI and TDF 
(Whitcomb, Parkin et al. 2003). These mutations have been selected out 
preferentially in persons who have received ARV therapy in pre-HAART era 
with incompletely suppressive thymidine analogue mono- or dual therapy. 
TAMs accumulate in two distinct but overlapping pathways (Marcelin, 
Delaugerre et al. 2004; Rhee, Liu et al. 2004; Cozzi-Lepri, Ruiz et al. 2005; 
Molina, Marcelin et al. 2005; Shafer and Schapiro 2008). The first (type I) 
pathway includes mutations M41L, L210W, T215Y, and the second (type II) 
the mutations D67N, K70R, T215F and K219QE. In the absence of drug 
pressure the T215YF mutation tend to revert to T215CDEISV but not back to 
its wild-type form, being therefore a marker for the presence of the original 
T215YF mutation (Yerly, Rakik et al. 1998; De Luca, Giambenedetto et al. 
2007; Shafer and Schapiro 2008).  
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2.2.3.2 NNRTI drug resistance mutations 
 
NNRTI DRMs are divided into primary, secondary, minor non-polymorphic 
and minor polymorphic accessory mutations. The NNRTI resistance is 
described as low genetic barrier resistance because only one primary DRM con-
fers high-level cross-resistance against all first generation NNRTIs (Shafer and 
Schapiro 2008). 
Primary NNRTI mutations in order of their frequency are K103NS, 
V106AM, Y181CIV, Y188LCH, G190ASE and are accompanied by the 
secondary mutations like L100I, K101P, P225H, F227L M230L and K238T 
(Bacheler, Jeffrey et al. 2001; Rhee, Taylor et al. 2006). Less commonly 
emerging mutations are V179F, F227C, L234I and L381F. The minor non-
polymorphic NNRTI mutations A98G, K101E, V108I and V179DE occur with 
or without primary NNRTI DRMs and they confer only low level resistance 
against NNRTIs (Rhee, Gonzales et al. 2003). Contrary to the first generation 
NNRTIs the full scale resistance development against the second generation 
NNRTIs needs the selection of at least two or more primary DRMs (L100I, 
Y181CI, G190E, M230L and in rarer cases V179IF and Y318F (Scherrer, 
Hasse et al. 2009; Johnson, Brun-Vezinet et al. 2010).  
 
 
2.2.3.3 PI drug resistance mutations 
 
According to the impact on DR these mutations can be divided into major 
(primary) and accessory (secondary) PI DRMs. Based on their location PI DRM 
can also be divided into PR substrate cleft, PR flap and PR other conserved 
residues and polymorphic positions mutations. Recently the gag cleavage site 
mutations associated with PI drug resistance have been described (Shafer 2002).  
Major or primary PI DRMs are localized in the 17 PR positions. Of them 
L23I, D30N, V32I, I47VA, G48V, I50VL, V82AFTS, I84V locate in PR 
substrate cleft region, M46IL and I54ML in the flap region and L76V, N88S 
and L90M in the interior of PR enzyme. Four PI DRMs (L24I, L33F, F53L and 
G73ST) possess antagonistic effect which means that by conferring resistance to 
one group of PIs they increase the susceptibility to the other group of PIs 
(Dauber, Ziermann et al. 2002; Vermeiren, van Craenenbroeck et al. 2007; 
Shafer and Schapiro 2008). 
Accessory or secondary PI DRMs do not confer direct resistance but restore 
the viral replication capacity in the presence of primary PI mutations (Shafer 
and Schapiro 2008). Based on their natural presence mainly in non-B subtype 
viruses these mutations or in this case polymorphisms could be divided into two 
categories. The first one involves substitutions selected out mainly by the ARV 
therapy. They generally do not account naturally for more than 10% of viruses 
of different subtypes. Most well-known of them are L10IV and A71VT or 
L10FR and A71IL, which are present in TN or TE patients, respectively (Shafer 
and Schapiro 2005). In several recent studies rare naturally occurring sub-
stitutions like V11I, E34Q, E35G, K43T, K45I, K55R, Q58E, T74PAS, V75I, 
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N83D, P79AS, I85V, L89V, T91S, Q92K and C95F have been described. Many 
of them have been associated mainly with darunavir or tipranavir exposure (Wu, 
Schiffer et al. 2003; Rhee, Fessel et al. 2005; Scherer 2007; De Meyer, 
Vangeneugden et al. 2008; Meyer 2008). The second category of accessory PI 
DRMs are present in highly polymorphic positions like 20, 36 and 63 and have 
been discussed in chapter describing natural polymorphisms (see 2.3).  
In addition several mutations selected during PI containing regimens have 
been localized in the protease cleavage site regions, especially into two cleavage 
sites: NC/p1 and p1/p6. The cleavages of these sites are potential rate limiting 
steps in viral protein maturation (Cote, Brumme et al. 2001; Dauber, Ziermann 
et al. 2002; Lambert-Niclot, Flandre et al. 2008).  
 
 
2.2.3.4 INI drug resistance mutations 
 
Similarly to NRTI DRMs the INI DRM can be divided into primary and 
secondary DRMs (Metifiot, Marchand et al. 2010). Majority of them situate in 
the binding pocket of INIs. Four DRM pathways have been associated with INI 
DR. The two most frequent are pathways initiated by the primary mutations 
N155H and Q148HRK which are accompanied by one or more additional 
secondary mutations like the L74M, E138A, E138K, G140S and the L74M, 
E92Q, T97A, Y143H, G163KR, V151I, or D232N, respectively (Malet, Delelis 
et al. 2008; Johnson, Brun-Vezinet et al. 2010). The pathways initiated by 
primary mutations Y143RHC and E92Q have been found less frequently 
(Malet, Delelis et al. 2008; Johnson, Brun-Vezinet et al. 2010). 
 
 
2.2.3.5 HIV-1 tropism and drug resistance  
mutations against entry inhibitors 
 
The HIV-1 possesses two DR mechanisms against viral entry inhibitors. Firstly, 
both ARV agents are able to inhibit mainly R5 tropic viruses (use only CCR5 
receptor for the cell entry). Therefore the virologic failure against these drugs 
can emerge by outgrow of X4 or dual tropic viruses (Reeves, Miamidian et al. 
2004; Xu, Pozniak et al. 2005). The changes in viral tropism have been 
correlated mainly with env V3 positions 11 and 25 charge changes (De Jong, De 
Ronde et al. 1992).  
Additionally, both drugs are able to select out classical DRMs independently 
from viral tropism. In case of fusion inhibitor ENF such resistance is associated 
primarily with mutations G36DS, I37V, V38AME, Q39R, Q40H, N42T, or 
N43D in the first heptad repeat (HR1) region of the gp41 envelope gene 
(Reeves, Miamidian et al. 2004; Xu, Pozniak et al. 2005). However, mutations 
or polymorphisms in other regions of the envelope (e.g. the HR2 region) may 
affect susceptibility as well (Reeves, Miamidian et al. 2004; Xu, Pozniak et al. 
2005). With maraviroc the DRMs which allow virus binding to drug-CCR5 
receptor complex have been described. Majority of these mutations locate in V3 
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loop or gp41 region, however there is no consensus about specific signature of 
these mutations (Johnson, Brun-Vezinet et al. 2010; Seclen, Gonzalez Mdel et 
al. 2010). 
 
2.2.4 Transmitted drug resistance mutations 
 
TDR is HIV-1 ARV resistance which has been aquired by transmission of drug 
resistant viruses. TDR mutation has the potential to limit therapeutic options in 
newly infected patients undergoing ARV therapy. The worldwide levels of TDR 
vary greatly and change over time (Wensing and Boucher 2003). The highest 
levels of TDR have been observed in developed countries of Western-Europe 
and North-America, the areas with wide access to ARV agents and with 
relatively long history of ARV monotherapy. The highest rates (22%) of TDR 
mutations are seen in Los Angeles (Booth, Garcia-Diaz et al. 2007; Hurt, 
McCoy et al. 2009). The rates in Western-Europe are somewhat lower re-
maining at the level of 10  20% of newly diagnosed patients (Wensing, van de 
Vijver et al. 2005; Spread programme 2008; Vercauteren, Wensing et al. 2009).  
The rate of TDR mutations in many European countries has followed 
specific trends. In 1990s the level of TDR was rapidly increasing until the early 
years of 2000 most likely as a consequence of mono- or dual therapy. Since 
then the level of TDR mutations has stabilized or even decreased below 10% 
(Spread programme 2008; Yerly, Junier et al. 2009; Descamps, Chaix et al. 
2010). Similar dynamics have been described in US, however, the established 
stabilisation levels are about twice as high as in Europe  (Booth, Garcia-Diaz et 
al. 2007; Hurt, McCoy et al. 2009).  
Giving deeper insight into the pattern of TDR mutations it is evident that the 
prevalence of TAMs and T215YF or its revertants was higher during the mono- 
and dual therapy time as these mutations were selected out by the extensive use 
of non-suppressive regimens with thymidine analogues (ZDV and D4T). 
Introduction of HAART in mid-1990s, however, lead to preferred emergence of 
low genetic barrier mutations (e.g.  M184V) and mutations to NNRTIs and PIs. 
For the same reasons the TDR mutations pattern in Western countries has 
moved from high genetic barrier DRMs to low genetic barrier DRMs (Wensing, 
van de Vijver et al. 2005; Vercauteren, Wensing et al. 2009). In terms of ARV 
classes the SPREAD study demonstrated that at present time the most common 
DRMs are NRTIs (5%) followed by PIs (3%) and NNRTIs (3%) mutations 
(Spread programme 2008; Chilton, Castro et al. 2010). The results of other 
studies conducted in individual Western-European countries (United Kingdom,  
France) confirm these findings (Paraskevis, Pybus et al. 2009; Chilton, Castro et 
al. 2010; Descamps, Chaix et al. 2010). Furthermore the Western-European 
studies have observed that TDR mutations is more frequently found in subtype 
B as compared to non-B subtype viruses (Spread programme 2008; Chilton, 
Castro et al. 2010).  
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2.2.4.1 Transmitted drug resistance mutations in Eastern–Europe 
 
The data about TDR in Eastern-Europe, especially in countries of rapidly 
developing IVDUs HIV-1 epidemics are limited (Zarandia, Tsertsvadze et al. 
2006; Santoro, Ciccozzi et al. 2008; Rumyantseva, Olkhovskiy et al. 2009). The 
most comprehensive data come from Eastern-European countries were the so-
called Western-European type of HIV-1 epidemics is spreading especially from 
Hungary and Poland (Wensing, van de Vijver et al. 2005). In these countries the 
prevalence of TDR has fluctuated between 4% and 29%, however in most cases 
it has remained below the 10% (Juhasz, Ghidan et al. 2008; Kanizsai, Ghidan et 
al. 2010; Stanczak, Stanczak et al. 2011). In lesser extent the TDR has been 
investigated also in Romania, Slovenia and Bulgaria were the TDR remained in 
the range of 0%-10% (Babic, Seme et al. 2006; Paraschiv, Otelea et al. 2007; 
Santoro, Ciccozzi et al. 2008).  
In the area of so called Eastern-Europe IVDU epidemics the most thoroughly 
investigated region is Latvia, showing the TDR prevalence of 3.4 %  28% 
(Kolupajeva, Aldins et al. 2008; Balode, Westman et al. 2010). Some  studies 
have also been conducted in Russia, Moldova and Georgia indicating the levels 
between 0-4% (Pandrea, Descamps et al. 2001; Smolskaya, Liitsola et al. 2006; 
Zarandia, Tsertsvadze et al. 2006; Kolupajeva, Aldins et al. 2008; Rumyant-
seva, Olkhovskiy et al. 2009; Balode, Westman et al. 2010; Vinogradova, 
Gafurova et al. 2010). However, one should bear in mind that most Eastern-
European studies are small in sample size, analyse together TN and TE 
populations and/or include patients infected with various viral subtypes 
(Paraschiv, Otelea et al. 2007; Kolupajeva, Aldins et al. 2008; Santoro, Ciccozzi 
et al. 2008; Vinogradova, Gafurova et al. 2010). 
 
 
2.3 Naturally occurring polymorphisms 
 
HIV-1 possesses several natural polymorphisms in ARV target regions 
especially in PR sequences (van de Vijver, Wensing et al. 2006). By definition 
natural polymorphisms have been described as aa difference of HIV-1 subtype 
B consensus sequences that are found withmore than 1% prevalence in certain 
HIV-1 population. Natural polymorphisms usually locate in non-active site 
regions allowing therefore variations by the genetic drift or by immune 
selection (Kantor and Katzenstein 2003). Interestingly many of these natural 
polymorphisms which are spread mainly in non-B viruses are selected out by 
ARV therapy in subtype B referring to their potential impact on DR. The 
prevalence of natural polymorphisms have been extensively characterized in 
widely spread HIV-1 subtypes such as A, B, C, CRF01_AE and CRF02_AG 
(Geretti 2006). 
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2.3.1 Protease polymorphisms 
 
A total of 30 PR aa and 99 RT aa positions are described as polymorphic in 
group M HIV-1 subtypes and CRFs (Kantor and Katzenstein 2003). Most 
widely spread of them locate in PR positions 20, 36, 63, 71, 77 and 93 (Shafer, 
Kantor et al. 2000; Kantor and Katzenstein 2003). Similarly to secondary 
DRMs these polymorphisms do not cause direct resistance to ARVs but rather 
compensate or restore the DRM possessing virus replication capacity (Martinez-
Picado, Savara et al. 1999; Nijhuis, Schuurman et al. 1999; van Maarseveen, de 
Jong et al. 2006). Their direct impact to the emergence of DR is unclear. Only 
once it has been described in vivo that PR M36I facilitates the emergence of PR 
resistance (Perno, Cozzi-Lepri et al. 2001). Naturally the most widely spread PR 
polymorphisms that have been associated with the ARV therapy are M36I, 
R41K, H69K, L89M; the well known consensus sequences in all so far inves-
tigated non-B subtypes (hivdb.stanford.edu) (Rhee, Kantor et al. 2006). The 
sole exception is subtype D which does not possess polymorphisms H69K and 
L89M most likely because of its higher similarity to subtype B. Other poly-
morphisms have been presented as consensus aa in a lesser extent  L10IV in 
subtypes A, G, CRF01_AE and CRF02_AG; K20I in subtypes F, G and 
CRF02_AG, E35D in subtypes A, F and CRF01_AE. In other subtyes these PR 
associated polymorphisms have been presented less frequently 
(hivdb.stanford.edu) (Rhee, Kantor et al. 2006).  
 
 
2.3.2 Reverse transcriptase polymorphisms 
 
Of the first 240 RT aa positions 41 have been indicated as polymorphic in 
different subtypes and CRFs (Shafer and Shapiro 2008). Of the 41 the aa 
codons 69 (in subtype F), 75 (in CRF01_AE), and 118 (in subtypes A, B, D) 
have been associated with NRTI and positions 98 (in subtypes B, C, and G), 
106 (subtypes G, AE and CRF02_AG) and 179 (subtypes B, C, D, F, G, 
CRF02_AG) with NNRTI resistance (Hirsch, Brun-Vezinet et al. 2000; Shafer 
2002). In rare cases two accessory mutations E44DA and V118I belonging to 
type I TAM pathway have been reported also as natural polymorphisms because 
of their occurrence in more than 1% of ARV naive viruses (Kantor and 
Katzenstein 2003). Additionally, the polymorphism F214L is described to 
increase the genetic barrier against type I TAMs (Shafer and Schapiro 2008; 
Spread programme 2008).  
 
 
 
2.3.3 Integrase polymorphisms 
 
Of 288 IN aa positions 115 have been described as polymorphic in different 
subtypes (Rhee, Liu et al. 2008). From them the substitutions S153A and 
E157Q are directly associated with DR and presented in about 1% of different 
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HIV-1 subtype sequences (Rhee, Liu et al. 2008). Other polymorphisms 
indirectly associated with DR such as I72V, L74M, T97A, S119GR, V151I, 
K156N, E157Q, G163KR, V165I, V201I, I203M, T206S and S230N have been 
found in much greater frequency. From them the substitutions V201I, I72V and 
T206S are most widely spread. V201I is consensus aa in all non-B subtypes, 
I72V in subtypes A, D, F, CRF01_AE, and T206S in subtype G and CRF02AG 
(Myers and Pillay 2008; Rhee, Liu et al. 2008; Ceccherini-Silberstein, Malet et 
al. 2009; Eshleman, Hudelson et al. 2009; Garrido, Geretti et al. 2010).  
Recent phenotypic DRM tests have demonstrated that in the absence of 
primary DRMs the role of the abovementioned polymorphisms in INI 
susceptibility is minimal in B as well as in non- B subtype viruses (van Baelen, 
van Eygen et al. 2008; Low, Prada et al. 2009). 
 
 
2.4 The subtype specific differences  
in drug resistance development 
 
Several studies have demonstrated that in general most DRMs are similar and 
equally selected by all HIV-1 subtypes and CRFs under the same ARV treatmen 
(van de Vijver, Wensing et al. 2010). However, the growing number of investi-
gations has shown that the subtype specific development of DRMs in different 
subtypes exists.  
In PR region the most thoroughly described is the preferred selection of 
L90M mutation in subtypes C, G, F and CRF01_AE compared to D30N in 
subtype B (Cane, de Ruiter et al. 2001; Sugiura, Matsuda et al. 2002; Grossman, 
Paxinos et al. 2004) during treatment with PIs. The preferred emergence of 
L90M has been associated with presence of M89IV (a widely described poly-
morphism in non-B subtype viruses) and with polymorphisms N83T and 74S 
specifically in subtype G viruses (Abecasis, Deforche et al. 2005; Calazans, 
Brindeiro et al. 2005; Martinez-Cajas, Pant-Pai et al. 2008). All these poly-
morphisms are able to restore the replication capacity of L90M carring viruses 
(Abecasis, Deforche et al. 2005).   
Another subtype specific response to ARV therapy has been found in 
CRF01_AE viruses exposed to NFV. In these cases the non-active site mutation 
N88S develops instead of D30N and N88D as described in subtype B viruses 
(Ariyoshi, Matsuda et al. 2003; Bandaranayake, Kolli et al. 2010).  
Most widely described suptype specific difference among NRTI DRMs is 
the selection of K65R. This mutation is rare in subtype A compared to subtype 
B and C viruses (Gupta, Chrystie et al. 2005). However, in studies using single 
dose of NVP K65R emerges less likely in subtype D and C than in subtype A 
viruses (Eshleman, Hoover et al. 2005). In cell culture studies the faster 
selection of K65R was also found in subtype C compared to subtype B viruses 
(Brenner, Oliveira et al. 2006). 
The subtype specific effect of NNRTI DRM emerges most strongly in RT 
position 106. In subtype B viruses mainly the V106A and in subtype C the 
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V106M will be selected (Brenner, Turner et al. 2003; Morris, Pillay et al. 2003; 
Grossman, Istomin et al. 2004). The likely explanation of preferred selection of 
V106M in subtype C is the change of a single nucleotide (from GTG to ATG) 
while in subtype B the emergence of the same DRM would require at least two 
bp substitutions (Brenner, Turner et al. 2003). Clinically the V106A confers 
resistance only to NVP but V106M is able to cause resistance to all first 
generation NNRTIs (Martinez-Cajas, Pant-Pai et al. 2008).   
 
 
2.5 Literature summary 
 
Within the last 15 years the HIV-1 epidemic has emerged in Eastern-Europe; 
mainly IVDUs are affected and the epidemics are caused mostly by the mono-
phyletic HIV-1 strains originating from subtype A1. In Estonia, however, the 
HIV-1 epidemic is similar to that described in Eastern-Europe, except that the 
infection is caused by the rare recombinant form CRF06_cpx instead. 
Recent studies have revealed that different subtypes and CRFs possess many 
polymorphisms in ARV agents target regions. However, mainly there have been 
investigated the widely spread subtypes and CRFs. Therefore there is very 
limited information about the subtype specific substitutions and DRM in 
Eastern-European HIV-1 strains and especially about the CRF06_cpx strain 
circulating in Estonia. The last one has been described so far only in single 
studies from resource poor-settings in Central-Africa.  
In addition, the management of HIV-1 infection may further be complicated 
by the development of TDR. In Western Europe where ARV therapy (including 
mono- and dual therapy) has been used for almost two decades about 10% of 
newly infected subjects carry DR viruses. In Eastern-Europe, including Estonia 
the situation has been poorly described so far. It is likely that it differs from 
mature epidemics because here the mono- and dual therapy has hardly been in 
use. On the other hand within last five years the consumption of ARV agents 
has strikingly increased in Estonia.  
So far the HIV-1 scientific investigations in Estonia have been conducted 
mainly by prof. Mart Ustav and by prof. Anneli Uusküla groups. In both groups 
there have been defended two Ph.D thesis by Maarja Adojaan and Kristi Rüütel. 
Maarja Adojaan’s works concentrate mainly on Estonian HIV-1 infections 
molecular epidemiology, host genetic factors and some aspects of the develop-
ment of HIV-1 vaccine (Adojaan, Kivisild et al. 2005; Adojaan, Molder et al. 
2007; Martinon, Kaldma et al. 2009; Molder, Adojaan et al. 2009). Kristi 
Rüütel´s studies investigated the epidemiological aspects of Estonian HIV-1 
infection including the risk-behaviour (IVDU) and quality of life of people 
living with HIV-1 (Platt, Bobrova et al. 2006; Ruutel, Uuskula et al. 2008; 
Ruutel, Pisarev et al. 2009). 
-
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3. AIMS OF THE RESEARCH 
 
The general aim of the research was to describe ARV resistance profile of the 
HIV-1 viruses circulating among the TN and TE subjects in Estonia during the 
concentrated HIV-1 epidemic.  
The study had following specific aims:  
1.  To describe the V3, PR, RT and IN regions of HIV-1 viruses circulating in 
Estonia in 2005 to 2006 and 2008.  
2.  To describe natural polymorphisms in PR, RT and IN regions of HIV-1 
viruses among TN subjects in Estonia.  
3.  To describe the association between the primary DRM in the RT region and 
IN polymorphisms in Estonia. 
4.  To characterize trends of TDR among HIV-1 positive subjects in 2005-2006 
and 2008 in Estonia. 
5.  To characterize primary DRMs in HIV-1 CRF06_cpx viruses in TE patients 
who have failed at least one ARV regimen. 
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4. PATIENTS AND METHODS 
 
The studies and analyses forming the basis of this thesis are presented in Table 2.  
 
 
4.1 Study design 
 
Current study involves five different populations (Table 2). 
The TN PR-RT and TN IN studies monitored naturally occurring DRMs and 
polymorphisms in PR-RT and IN regions in TN patients. The TE IN study 
aimed to find out the PR-RT DRM associated substitutions in IN region among 
TE patients infected with viruses possessing at least one DRM in RT region. 
The TDR mutations study investigated the prevalence of TDR mutations among 
newly diagnosed TN patients three years after the scale-up of ARV therapy in 
Estonia and the TE PR-RT study described the DRM among TE patients who 
have failed ARV therapy.   
Subjects of the first two studies were invited by their treating physician to 
donate 8-16 ml blood for HIV-1 genotyping and fill in a questionnaire including 
demographic (date of birth, sex, nationality, risk behaviours, possible date of 
infection and possible route of transmission) and clinical characteristics (viral 
load and CD4+ cell count). The route of transmission was considered as 
intravenous if the intravenous drug use episodes were reported regardless of the 
sexual contact with HIV positive subject; heterosexual if the subject had been in 
sexual contact with the HIV positive person and had no other risk factors; or 
unknown if the subject denied having known risk factors of HIV-1 infection. 
The TN PR-RT and TN IN studies consisted of subjects originating from Ida-
Viru County (epicentre of the epidemic) and Tartu prison.   
All populations were representative selection of Estonian HIV positive 
subjects who are mainly young male IVDUs originating from Tallinn, the 
capital of Estonia, or Ida-Viru County (Laisaar, Avi et al. 2011). All patients 
had been tested HIV positive during the concentrated HIV-1 epidemic between 
2000 and 2010. 
In all populations the presence of HIV-1 infection was first tested with the 
fourth generation enzyme-linked immunoassay (Vironistica HIV Uniform II 
Ag/Ab, BioMerieux, Marcy Etoile, France) at local HIV testing laboratories and 
then verified by the immunoblotting assay (INNO LIA HIV I/II Score Western-
blot, Microgen Bioproducts Ltd, Surrey, UK) in the HIV Reference Laboratory 
of the West Tallinn Central Hospital.  
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Table 2. Description of studies incorporated into this thesis  
 
 Study design Sampling 
period 
Study 
population 
Primary aim Publi-
cation 
1/Evaluation of 
natural DRMs and 
polymorphisms 
among TN subjects 
in PR-RT region  
(TN PR-RT 
population) 
September 
2005–
October 
2006 
115 TN sub-
jects diagnosed 
HIV positive in 
2000-2005 
from Ida-Viru 
region and 
Tartu Prison  
To determine natural 
DRM and poly-
morphisms in Estonian 
HIV-1 CRF06_cpx 
viruses in PR and RT 
region 
1 
2/ Evaluation of 
natural DRMs and 
polymorphisms 
among TN subjects 
in IN region (TN IN 
population) 
September 
2005–
October 
2006, April–
May 2007 
104* 
same as study 1 
To determine the 
natural DRM and 
polymorphisms 
spreading in Estonian 
HIV-1 CRF06_cpx 
viruses in IN region 
2 
3/Monitoring of IN 
region 
polymorphisms 
among TE 
population  
(TE IN population) 
October 
2006 – May 
2007 
10** To describe the 
association between IN 
region polymorphisms 
and RT region primary 
DRMs in HIV-1 
CRF06_cpx  
2 
4/TDR mutations  
monitoring after 
scale-up of ARV 
therapy  
(TDR population) 
April 2008 – 
November 
2008 
201*** TN 
subjects with 
newly 
diagnosed HIV 
infection 
To describe the 
prevalence of TDR 
among newly 
diagnosed HIV-1 
positive subjects in 
2008 
3 
5/Monitoring of 
DRMs in PR-RT 
region among TE 
subjects  
(TE PR-RT 
population) 
September 
2006 –
November 
2010 
97** To describe the DRM 
in TE subjects who 
failed at least one ARV 
regimen 
– 
* 77 subjects of this population overlap with TN PR-RT study subjects; the additional 27 samples 
were collected in the syringe exchange programs from Ida-Viru County and Tallinn in April-May 
2007  
** TE IN and TE PR-RT study populations consisted of patients in Ida-Viru Central Hospital who 
had been diagnosed HIV-1 positive in 2000–2007 and 2000–2010, respectively. Their treating 
physician had diagnosed their ARV treatment failure and their blood samples were sent to Tartu 
University Clinics for HIV-1 drug resistance testing. In case of TE IN study population subjects 
whose viruses possessed at least one DRM in HIV-1 RT or PR region were involved. 
*** Samples consisted of leftovers of plasma samples sent from the first level HIV screening 
centers, anonymous cabinets and by physisians suspecting HIV-1 infection to the HIV Reference 
Laboratory of the West Tallinn Central Hospital for the HIV confirmatory testing.  
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4.2 Ethical considerations 
 
The protocols of TN PR-RT and TN IN studies have been approved by the 
Ethics Review Committee on Human Research of the University of Tartu 
(142/8, 24th of October, 2005) and subjects signed informed consents under the 
supervision of their treating physicians. The results of HIV-1 PR-RT geno-
typing and their interpretations have been made available for patients and their 
physicians. In TE IN, TDR and TE PR-RT studies the approval of the Ethics 
Review Committee was considered unnecessary as surplus of non-personalized 
sera were used.    
 
 
4.3 Blood sample collection and processing 
 
In all studies except the TDR study appoximately 20 ml blood was taken via 
venepuncture into BD Vacutainer Cell Preparation Tubes (BD Diagnostics, 
Becton Dickinson, USA) and centrifuged at 3000 rpm for 30 min in the 
laboratory of Institute of Microbiology within 4 hours after collection. In TDR 
study at least 400 μl of plasma was obtained after the HIV confirmatory testing 
in the HIV Reference Laboratory. All samples were stored at the – 80oC until 
further analysis but no longer than for 6 months. The viral genomic RNA was 
extracted from 0.4 ml of plasma using the QIAamp Viral RNA Mini Kits 
(Qiagen, Germany) as recommended by the manufacturer and stored at – 80 C o 
for a maximum of 6 months.  
 
 
4.4 Reverse transcription and PCR 
 
The HIV-1 genotyping in different regions was conducted using modified 
protocols published elsewhere (Liitsola, Laukkanen et al. 1996; Nijhuis, 
Schuurman et al. 1999; Zetterberg, Ustina et al. 2004; Adojaan, Kivisild et al. 
2005; Lataillade, Chiarella et al. 2010). The PR-RT protocol was originally 
developed by prof. Jan Albert (Karolinska Institutet, Stockholm, Sweden)  
The viral genomic RNA was reverse transcribed, amplified and sequenced in 
following regions:  
 PR region (2,139-2,647 bp in HXB2) – in TN PR-RT population 
 RT region (2,533- 3,331 bp in HXB2) – in TN PR-RT population 
 env region (6,962-7,371 bp in HXB2) – in TN PR-RT population 
 IN region (4,141- 5,219 bp in HXB2) – in TN IN and TE IN population  
 PR-RT region (2,242- 3,333 bp in HXB2) – in TE IN, TDR and TE PR-RT 
population 
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4.4.1 PR, RT and env region amplification in TN PR-RT population 
 
In PR, RT, and env regions reverse transcription and the first round PCR was 
performed using 4 μl of viral genomic RNA, Illustra Ready-to-Go RT-PCR Beads 
(GE Healthcare, UK) and corresponding primers for PR, RT and env regions as 
shown in Supplemental Table 1 (Article 1). Then 2 μl of the first round PCR 
product was transferred to the second round PCR. One unit of 6:1 mixture of Taq 
and Pfu (Fermentas, Lithuania) DNA polymerase and 0.3 μM primers 
(Supplemental Table 1 in Article 1) were used in the second round PCRs.  
 
 
4.4.2 PR-RT region amplification in TE IN and TDR populations 
 
In PR-RT region the HIV-1 RNA was reverse transcriptased into cDNA using 
the following conditions: 1x reaction buffer, 1mM dNTP, 16U M-MuLV RT 
(Fermentas, Lithuania), 16U RNase inhibitor (Invitrogen, USA), and 0.4 μM 
antisense primer JA272degen (5′-GGATAAATMTGACTTGCCCART-3′). PR-
RT region was amplified in a first round PCR using the following conditions: 
1x HotStart Buffer, 1.5 mM MgCl2, 0.2 μM dNTP, 0.4 μM primer JA269degen 
(5′-AGGAAGGMCACARATGAARGA-3′) and JA272degen. Second round 
PCR was carried out in the same conditions as the first round using primers 
JA270 (5′-GCTTCCCTCARATCACTCTT-3′) and JA271 (5′-CCACTAAYT 
TCTGTATRTCATTGAC-3′). One unit of 6:1 mixture of Taq and Pfu DNA 
polymerase (Fermentas, Lithuania) was used in both PCR rounds.   
 
 
4.4.3 IN region amplification in TN IN and TE IN populations 
 
In IN region the HIV-1 RNA was reverse transcriptased into cDNA using the 
following conditions: 1x reaction buffer, 1mM dNTP (Fermentas, Lithuania), 
16U M-MuLV RT (Fermentas, Lithuania), 16U RNase inhibitor (Invitrogen, 
USA), and 0.4 μM antisense primer INREV-Idegen (5′-TCTCCTGTATGCA 
GACCCCAATAT-3′). IN region was amplified in a first round PCR using the 
following conditions: 1x HotStart Buffer, 1.5 mM MgCl2, 0.2 μM dNTP, 
0.4 μM primer INFORIdegen (5′-GGAATYATTCARGCACAACCAGA-3′) 
and 0.4 μM primer INREV-Idegen. Second round PCR was carried out in the 
same conditions as the first round using primers HIV+4141degen (5′-TCTA 
YCTGKCATGGGTACCA-3′) and INREVII (5′-CCTAGTGGGATGTGTACT 
TCTGA-3′). One unit of 6:1 mixture of Taq and Pfu DNA polymerase 
(Fermentas, Lithuania) was used in both PCR rounds.  
 
 
4.5 Sequencing 
 
All second round PCR products were purified with the QIAquick PCR 
Purification Kit (Qiagen, Germany) and directly sequenced using the ABI Prism 
Big Dye 3.0 fluorescent terminator sequencing chemistry (Applied Biosystems, 
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USA) with the second round PCR primers and in the PR-RT region in 
additional sequencing primers JA273 (5′-CCCTCAAATCACTCTTTGGC-3′), 
JA274 (5′-AAAATCCATACAATACTCCA-3′), JA275 (5′-TTATTGAGTT 
CTCTGAAATC-3′) and JA276 (5′-TGTATATCATTGACAGTCCA-3′). 
 
 
4.6 Sequence analysis 
 
Sequences were assembled to contiques using the Vector NTI software 
(Invitrogen, UK). Alignments were conducted by the MEGA 4.0 software 
packages and phylogenetic trees were constructed using the (NJ method as 
described elsewhere (Naganawa, Sato et al. 2002). All reference sequences were 
taken from the Los-Alamos HIV Sequence Database (www.hiv.lanl.gov). The 
statistical robustness of NJ trees and reliability of branching pattern were 
confirmed by bootstrapping (1000 replicates). Consensus sequences were 
constructed using MEGA 4.0 software package.  
For the aa frequency analysis the studied PR-RT and IN sequences were 
translated into aa sequences and were analysed by the MEGA 4.0 software 
packages comparing the aa composition in corresponding positions with 
subtype B reference sequence (HXB2 from Los Alamos HIV sequence database 
(www.hiv.lanl.gov)).  
Phylogenetic trees were constructed for TN PR-RT (in env and RT regions), 
TN IN and TE IN, and TDR population sequences using the following subtype 
and CRF reference sequences:  
For TN PR-RT population: AF004885, U51190, AF069670, AF484509, 
AF286238, AF286237, K03455, AY423387, AY173951, AY331295, U52953, 
U46016, AF067155, AY772699, K03454, AY371157, AY253311, U88824, 
AF077336, AF005494, AF075703, AJ249238, AY371158, AJ249236, 
AJ249237, AF377956, AF084936, AF061641, U88826, AF061642, AF190127, 
AF190128, AF005496, AF082394, AJ249235, AJ249239, U54771, L39106, 
AF193276, AF193253, AF064699, L20587, AY535659, DQ400856, 
AY500393,  AB286851, AJ245481, AJ288982, AF064699 and AJ288981.   
For TN IN and TE IN population: AF004885, AF286238, K03455, U52953, 
K03454, AF077336, AY371158, AF084936, AF190127, AF082394, AJ249235, 
U54771, L39106, AF193276, L20587, AJ245481, AJ288981, AB286851, 
AF064699, AY535660, AY500393, DQ167216, DQ400856, and AY535659.  
For TDR population: AF004885, DQ676872, AF286238, K03455, U52953, 
K03454, AF077336, AY371158, AF084936, AF190127, EF614151, AJ249235, 
U54771, AY271690, AF414006, AB286851, AJ245481, AF064699, 
AY500393, AY535659, DQ400856 and L20587. 
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4.7 Simplot analysis 
 
For determination the recombination structure of the putative recombinant 
forms sequences were analysed with the Simplot software using bootscanning 
method and following parameters: Window 200 bp, Step 20 bp, GapStrip: on, 
Reps 100, Kimura (2- parameter), T/t 2.0 and the NJ. The region similarity to 
certain subtype or CRF was confirmed if permutated tree value was higher than 
70%. Additionally, in TDR study population putative recombinant sequences 
were reanalysed with the Simplot bootscanning analysis using the window size 
of 400bp. The HIV-1 subtype reference sequences used in the Simplot analysis 
in corresponding regions were as follows: 
For TN PR-RT population: AF004885, AF286238, K03455, U52953, K03454, 
AF077336, AY371158, AF084936, AF190127, AF082394, AJ249235, L20587, 
AY500393 and AY535659. 
For TN IN and TE IN population: AF004885, AF286238, K03455, U52953, 
K03454, AF077336, AY371158, AF082394, AJ249235, AY500393 and 
AY535659. 
For TDR population: AF004885, AF286238, K03455, U52953, K03454, 
AF077336, AY371158, AF414006, AF084936, AF190127, EF614151, 
AJ249235, U54771, AY271690, AY500393 and AY535659. 
 
 
4.8 Determination  
of drug resistance mutations and polymorphisms 
 
4.8.1 For PR-RT region 
 
DR associated polymorphisms, DRM and DR interpretations were conducted in 
TN PR-RT population for PR and RT sequences using the International AIDS 
Society-USA database (www.iasusa.org) or Stanford University HIV Drug 
Resistance Database Genotypic Resistance Interpretation Algorithm (Version 
4.3.1) and for IN and TDR populations using Stanford University HIV Drug 
Resistance Database Genotypic Resistance Interpretation Algorithm (Version 
4.3.1). 
 
 
4.8.2 For IN region 
 
The aa polymorphisms in every IN position were analyzed using subtype B 
consensus sequence from Los Alamos HIV sequence database 
(www.hiv.lanl.gov). The functionally conserved motifs (DDE, HHCC), 
extended active site residues (Q62, C65, T66, H67, E92, N120, F121, I141, 
P142, Y143, Q148, V151, N155, K156, K159) and LEGP/p75 site residues 
(R166, D167, Q168, A169, E179 and H171) were evaluated (Rhee, Liu et al. 
2008). INI drug resistance associated polymorphisms and INI DRM list were 
used as described by Myers and Pillay (Myers and Pillay 2008). The 
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substitutions were then characterized in three groups according to their 
influence on viral replication in the presence of INIs used in clinical trials or in 
vitro experiments as follows: the N155H, Q148KRH and E92Q were considered 
as primary INI DRMs, substitutions H51Y, T66I, L74MAI, T97A, F121Y, 
E138K, G140SA, Y143RC, S147G, V151I, S153Y, E157Q, G163R, I203M, 
S230R, and R263K were classified as accessory mutations and T125K, A128T, 
Q146K, S153A, M154I,  N155S, K156N, K160D, V165I, V201I, T206S, 
S230N, V249I, and C280Y were considered to be associated with non-clinical 
INI drug resistance (Myers and Pillay 2008; Rhee, Liu et al. 2008; Lataillade, 
Chiarella et al. 2010).  
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5. RESULTS AND DISCUSSION 
  
5.1 Study populations predominantly consisted  
of intravenously infected subjects 
 
As presented in Table 3 all study populations for which demographic data were 
available consisted predominantly of young male IVDUs.   
 
Table 3. Demographic and clinical characteristics of the study populations 
 
Study 
No 
Study 
population 
Median age 
(IQR) 
Percentage 
of IVDUs 
N of  
subjects – 
total/%male 
Median 
CD4 
cells/ml 
(SD) 
Median VL 
copies/ml (SD) 
1 TN PR-RT 27(24;30) 65 115/70 417 (+-284) 
190,271  
(+-395,994) 
2  TN IN 27 (23;30) 66 104/84 414  (+-297) 
175,200  
(+-349,866) 
3 TE IN no data no data  10/no data 174  (+-82) 
63,163  
(+-55,781) 
4 TDR no data no data  201/61 no data no data 
5 TE PR-RT no data no data 83/no data 178  (+-160) 
45,013  
(+-762,338) 
 
 
5.2 The HIV-1 CRF06_cpx has been the most 
predominant subtype during the last 7 years  
 
Regardless of the investigated population or the year of the sample collection all 
sequenced regions demonstrated that CRF06_cpx was by far the most pre-
dominant subtype accounting for about 70% or more of cases (Table 4, Figure 
6, Figure 1 in Article 1, Figure 1 in Article 2 and Figure 1 in Article 3).  
 
Table 4. The distribution of Estonian HIV-1 subtypes and recombinant forms in diffe-
rent genomic regions based on the phylogenetic tree and Simplot analysis 
 
Study 
name  
Total 
number 
of 
subjects 
Number of 
sequenced 
samples in 
corresponding 
region 
HIV-1 subtypes n ( %) 
CRF06_cpx recomb ** A1 B CRF02_AG 
TN PR-RT 115 PR - 87 
RT - 56 
env - 67 
nd* 
49 (88) 
64 (96) 
nd* 
6 (11) 
0 
nd* 
1 (2) 
3 (4) 
nd* 
1 (2) 
0 
nd* 
0 
0 
TN IN 104 IN - 104 89 (86) 14 (13) 3 (3) 0 0 
TE IN 10 IN -10 7 (70) 1 (10) 0 1 (10) 1 
TDR 201 PR-RT - 145 123(85) 17 (12) 2 (1) 3 (2) 0 
TE PR-RT 83 PR-RT - 59 57 (97) 0 0 2 (3) 0 
* Sequenced PR genomic region was too short for phylogenetic tree analysis 
nd – no data 
**- recombinants between CRF06_cpx and subtype A1 or some other subtypes 
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The second largest group in almost all regions was a recombinant form of   
CRF06_cpx and subtypes A1 or other subtypes; the only exception was env 
region where the recombinant sequences were absent (Table 4). In phylogenetic 
analysis these recombinant sequences clustered outside other subtypes or CRFs 
reference sequences (bootstrap cut off <70%) or formed sub-clusters with long 
root branches inside other monophyletic clusters (Figure 1 in Article 1).  
Additionally in almost all analysed regions only single sequences (less than 
3%) belonged to subtype A1, subtype B or CRF02_AG clades (Table 4, Figure 
6, Figure 1 in Article 1, Figure 1 in Article 2 and Figure 1 in Article 3).  
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Figure 6. NJ tree of PR-RT sequences of the TE PR-RT population including reference 
sequences of all subtypes, CRF01_AE, CRF02_AG, and CRF06_cpx. The tree is rooted 
by the HIV-1 group O reference sequence. A genetic distance scale of 0.02 is indicated. 
Majority of Estonian TE PR-RT sequences cluster together with CRF06_cpx sequences.  
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The subtype distribution in the present studies was in good concordance with 
the earlier results in Estonia in 2000-2003 (Zetterberg, Ustina et al. 2004; 
Adojaan, Kivisild et al. 2005). These studies found that the phylogenetic 
distribution in gag/pol region consisted of 77% of CRF06_cpx and 10-16% of 
recombinant forms between CRF06_cpx and subtype A1. Moreover similar to 
us they did not found any CRF06_cpx and subtype A1 recombinants in env 
region (Zetterberg, Ustina et al. 2004; Adojaan, Kivisild et al. 2005). 
These results suggest that recombination in env region of Estonian HIV-1 
viruses might be impeded. One potential explanation could be the greater 
diversity of env compared to gag or pol sequences. However, to our best 
knowledge such preferred recombination in certain HIV-1 genomic regions has 
not been described before; rather there have been indications to equal 
distribution of recombination breakpoint throughout the entire HIV-1 genome 
(www.hiv.lanl.gov). 
As presented in Figure 1 in Article 1, Figure 1 in Article 2 and Figure 1 in 
Article 3 and similarly in Adojaan and Zetterberg the subtype A1 viruses clustered 
together with Eastern-European subtype A1 reference sequences suggesting that 
Estonian subtype A1 infected patients are  epidemiologically most likely linked to 
Eastern-European subtype A1 HIV-1 epidemics (Zetterberg, Ustina et al. 2004; 
Adojaan, Kivisild et al. 2005). 
The overwhelming predominance of CRF06_cpx strains for almost 10 years 
demonstrates the stability of the Estonian HIV-1 phylogenetic structure despite 
being potentially exposed to the HIV-1 subtype A1 and lesser extent CRF03_AB 
epidemics in surrounding countries like Latvia and Russia (Lukashov, Huismans 
et al. 1999; Smolskaya, Liitsola et al. 2006; Thomson, de Parga et al. 2007; 
Thomson, Vinogradova et al. 2009). At the same time the Estonian CRF06_cpx 
viral strains have also been restricted to Estonia. Only single cases of similar 
CRF06_cpx viruses have been reported in Russia, Sweden and Latvia; all 
emerged after the CRF06_cpx outbreak in Estonia (Skar, Sylvan et al. 2008; 
Rumyantseva, Olkhovskiy et al. 2009; Balode, Westman et al. 2010; Vino-
gradova, Gafurova et al. 2010). In the phylogenetic analysis these CRF06_cpx 
sequences cluster inside the Estonian CRF06_cpx viral clade suggesting their 
potential links to Estonian CRF06_cpx epidemic (Skar, Sylvan et al. 2008).  
This all refers that the Estonian HIV-1 CRF06_cpx epidemic is most likely 
seeded independently of other HIV-1 epidemics in former Soviet Union or 
neighboring countries and most probably originates directly from the West- or 
Central Africa, more specifically from Mali or Burkina Faso where the 
prevalence and diversity of CRF06_cpx viruses is the highest in the world 
(Montavon, Toure-Kane et al. 2002; Ouedraogo-Traore, Montavon et al. 2003; 
Tebit, Ganame et al. 2006). Furthermore the Estonian HIV-1 epidemic has not 
been influenced by our Nordic neighbors  Finland and Sweden as CRF06_cpx 
and its next generation recombinants in these countries are mostly not found 
(Liitsola, Holmstrom et al. 2000; Liitsola, Ristola et al. 2000; Kivela, Krol et al. 
2005; Kivela, Krol et al. 2007; Skar, Sylvan et al. 2008; Skar, Axelsson et al. 
2011).  
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5.3 Molecular characteristics  
of Estonian CRF06_cpx viruses 
 
In phylogenetic tree analysis all Estonian CRF06_cpx sequences in all genomic 
regions of current study form a single monophyletic cluster inside the 
CRF06_cpx sequences circulating in other countries (Figure 6, Figure 1 in 
Article 1, Figure 1 in Article 2 and Figure 1 in Article 3). Furthermore, in more 
conserved genomic regions (e.g. RT) the viral sequence homogeneity is so high 
that some viruses indicate the same or nearly identical sequences (Figure 1 in 
Article 1 and Figure 1 in Article 2). Therefore one can speculate that the PCR 
contamination can be the cause of such high similarity. However, highly similar 
or identical clusters have also been found recently in Estonia independent from 
our group (Zetterberg, Ustina et al. 2004; Adojaan, Kivisild et al. 2005). In 
addition nearly identical sequences among the Eastern-European HIV-1 subtype 
A1 infection have also been demonstrated within few years after the HIV-1 
outbreak in Ukraine (Novitsky, Montano et al. 1998; Nabatov, Kravchenko et 
al. 2002; Saad, Shcherbinskaya et al. 2006; Thomson, de Parga et al. 2007).  
 
 
5.4 Simplot analysis of putative recombinant forms 
between CRF06_cpx and other HIV-1 strains 
 
In TN PR-RT population six putative recombinant forms in RT region were 
analysed by Simplot software. All these sequences revealed similar recombi-
nation structure starting with the CRF06_cpx and ending with the subtype A1 
sequences.  
In TN IN and TE IN sequences 14 and 1 putative recombinant forms, 
respectively, represented complex structures between CRF06_cpx, subtype A1 
and CRF03_AB sequences. The recombination breakpoint analysis of these 
viruses revealed two similar sequence clusters consisting of five and three 
strains, respectively, and seven URFs.  
In the TDR population Simplot analysis was carried out using two window 
sizes (200 and 400 bp) for 17 putative recombinant PR-RT sequences. In both 
analyses all sequences turned out to be URFs between subtype A1, CRF06_cpx 
and CRF02_AG.  
Complex recombinant structure at Estonian HIV-1 viruses has also been 
described before by Adojaan et al (Adojaan, Kivisild et al. 2005). They 
sequenced two viral strains from these viruses and designated it as a new 
“Estonian born” HIV-1 circulating recombinant form CRF32_A106 (Figure 5B) 
(www.hiv.lanl.gov) (Adojaan, Kivisild et al. 2005). 
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5.5 Drug resistance mutations and polymorphisms  
in TN PR-RT sequences 
 
The samples of TN PR-RT population were collected before scaling-up of 
HAART in Estonia. There were no primary DRMs or accessory DRMs in PR or 
RT region. Thus all viruses in TN PR-RT population were susceptible to 
currently available RTIs and PIs.  
These results were largely expected for two reasons. Firstly, the use of ARV 
therapy in Estonia was very limited until 2006 (Figure 7). Secondly, the 
predominant CRF06_cpx viruses began to circulate in Estonian population with 
the emergence  of concentrated epidemic in 2000 – that is after the mono- and 
dual therapy period which was the main factor to induce TDR in developed 
countries (Salminen, Nykanen et al. 1993; Liitsola, Laukkanen et al. 1996; 
Ustina, Zilmer et al. 2001; Zetterberg, Ustina et al. 2004; Adojaan, Kivisild et 
al. 2005; Laisaar, Avi et al. 2011). 
These data suggest that absence of DRMs in CRF06_cpx viruses is similar to 
other HIV-1 subtype B and non-B viruses from the pre-ARV treatment period 
(Shafer 2002; Vergne, Diagbouga et al. 2006).  
On the contrary to the absence of primary and accessory DRMs the 
CRF06_cpx viruses are rich of well conserved drug resistance associated PR 
polymorphisms in TN PR-RT population (I13V, K14R, F17E, K20I, E35D, 
M36I, R41K, L63H, H69K and L89M). The same results were obtained in TDR 
population (Table 5). 
 
 
Table 5. The rate (%) of most frequent natural PR polymorphisms in Estonian HIV-1 
viruses 
 
PR polymorphisms
 
Study populations 
I1
3V
 
K
14
R
 
G
17
E 
K
20
I 
E3
5D
 
M
36
I 
R
41
K
 
L6
3H
 
H
69
K
 
L8
9M
 
TDR all  
n=139 97 93 81 91 82 97 95 77 100 98 
TDR CRF06_cpx n=123  99 94 89 98 80 99 93 85 100 97 
TN PR-RT all  94 96 74 87 90 100 92 92 99 100 
 
 
According to the frequency of these polymorphisms in HIV-1 CRFs they can be 
divided into three categories.  
The first category consists of PR polymorphisms M36I, H69K and L89M 
presented in more than 95% of strains circulating in Estonia. These substitutions 
are described in more than 90% of sequences of almost all non-B subtype 
viruses (Kantor and Katzenstein 2003; Kantor and Katzenstein 2004; Kantor, 
Katzenstein et al. 2005; Rhee, Kantor et al. 2006). The high prevalence of 
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M36I, H69K and L89M polymorphisms among CRF06_cpx viruses has also 
been  found in West-African studies from Burkina Faso, Mali and Hungary 
(Tebit, Sangare et al. 2009).  
The second category of PR polymorphisms includes I13V, K14R, G17E, 
K20I, E35D, L63H, which have been found in 70 to 99% of strains in current 
studies (Table 5). In non-B subtypes these substitutions are consensus aa in 
majority, but not all subtypes and CRFs (Kantor and Katzenstein 2003; Kantor 
and Katzenstein 2004; Kantor, Katzenstein et al. 2005; Rhee, Kantor et al. 
2006). In CRF06_cpx viruses from other countries these polymorphisms have 
been presented in almost all cases except the L63H which is found only in few 
viruses from Burkono Faso and Mali (hivdb.stanford.edu) (Rhee, Kantor et al. 
2006; van de Vijver, Wensing et al. 2006; Tebit, Sangare et al. 2009). This lets 
us suggest that the highly conserved L63H is unique to viruses circulating in 
Estonia. 
The third group consists of PR polymorphisms L10I, I15V, G17D, K43R, 
L63P, I64M, K70R, I72V, V82I, and I93M; all of them were rare (<10%) in 
CRF06_cpx in current study as well as in many other subtypes (Rhee, Kantor et 
al. 2006). From them only substitutions I15V, L63P and V82I are consensus 
sequences in subtypes C and F; B, C and D; and subtype G, respectively (Rhee, 
Kantor et al. 2006) (hivdb.stanford.edu).  
Two subtype A1 strains possessed polymorphisms E35D, M36I, N37D, 
H69K, L89M and I93L. These polymorphisms, except N37D and I93L, are also 
consensus sequences in other subtype A viruses (hivdb.stanford.edu). However, 
it is worth to mention that Estonian subtype A1 viruses did not carry the 
polymorphism V77I characteristic to Eastern-European subtype A1 subcluster 
and are shown to spread in several countries of former Soviet Union (Rou-
dinskii, Sukhanova et al. 2004; Zarandia, Tsertsvadze et al. 2006; Thomson, 
Vinogradova et al. 2009; Vinogradova, Gafurova et al. 2010).  
 
5.6 Integrase region drug resistance mutations and 
polymorphisms 
 
Similarly to PR and RT region no primary DRM were identified in IN region 
suggesting that all Estonian HIV-1 strains are susceptible to currently available 
INIs. These data are in good concordance with the results obtained in B and 
non-B subtypes indicating absence or very low prevalence of primary DRMs 
(<1%) in TN HIV-1 viruses (Rhee, Gonzales et al. 2003). However, because 
INIs have been introduced to the market only very recently (in 2007) it is not 
suprising that the IN region is less extensively investigated than the PR-RT 
region (Rhee, Liu et al. 2008; Ceccherini-Silberstein, Malet et al. 2009; Low, 
Prada et al. 2009; Passaes, Guimaraes et al. 2009; Ceccherini-Silberstein, van 
Baelen et al. 2010; Fish, Hewer et al. 2010; Lataillade, Chiarella et al. 2010). 
The sole exception among INI DRMs in our study is E157Q, found only in one 
strain. E157Q confers low level in vitro resistance (5-10x) to raltegravir and 
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elvitegravir (Ghosn, Mazet et al. 2009; Low, Prada et al. 2009; Varghese, Liu et 
al. 2010) and seems to be presented as natural polymorphisms in B and non-B 
subtypes with the prevalence rate of 1–2% of TN viruses. However, a higher 
frequency of this mutation (4%) was reported in a study in South-Africa 
invloving subtype C (Rhee, Liu et al. 2008; van Laethem, Schrooten et al. 2008; 
Eshleman, Hudelson et al. 2009; Passaes, Guimaraes et al. 2009; Fish, Hewer et 
al. 2010). 
Similar to PR region several accessory mutations and polymorphisms like 
72I1, L74I, V201I and T206S were found in more than 95% of Estonian HIV-1 
viruses in IN region. The most unique character was the absolute conservation 
of the IN polymorphisms L74I. The prevalence of L74I in other subtypes (e.g. 
B-D, F, G, CRF01_AE and CRF02_AG) is less than 20% (Rhee, Liu et al. 
2008). Substitution 72I was presented in 92% (105/114) of all viruses and in 
96% (85/89) of CRF06_cpx viruses. Different studies have demonstrated that 
this mutation is a consensus aa in the subtype A, B, D and CRF02-AG viruses 
(Rhee, Liu et al. 2008; Lataillade, Chiarella et al. 2010).  
From the substitutions associated with INI DR in vitro only the V201I and 
T206S were widely spread being presented in 97% (110/114) and 96% 
(109/114) of the entire population and 98% (87/89) and 99% (88/89) among 
CRF06_cpx viruses, respectively. Of these V201I is consensus aa in all non-B 
viruses, and in subtype B viruses it is presented in about 10–20% of cases 
(Rhee, Liu et al. 2008; Fish, Hewer et al. 2010; Lataillade, Chiarella et al. 
2010). The T206S is less prevalent being consensus aa only in CRF02_AG and 
subtype G viruses and in other subtypes including subtype B being presented 
approximately in 10% of cases. (Rhee, Liu et al. 2008).  
 
5.7 No compensatory integrase mutation was found in 
reverse transcriptase drug resistance possessing viruses 
 
Among 10 TE patients the association between HIV-1 RTI DRMs and possible 
substitutions in IN region was evaluated. No IN region polymorphisms 
associated with RTI DRMs were identified. This contrasts with the results of 
Ceccherini-Silberstein, who demonstrated the co-variation of RTI DRM F227L 
and T215Y with IN substitutions M154I and V165I (Ceccherini-Silberstein, 
Malet et al. 2009; Ceccherini-Silberstein, van Baelen et al. 2010). Several other 
studies, however, have not found these associations (Roquebert, Blum et al. 
2008; Passaes, Guimaraes et al. 2009). We have to mention that the absence of 
the association in the current study need to be treated with caution because of 
low sample size of our analysed population.  
                                                 
1 Isoleutcine in IN position 72 is consensus aa in majority of subtype B viruses, however 
among INI treated subtype B viruses this aa is overrepresented compared to INI naïve viral 
strains and therefore 72I have been considered as aa which is associated with INI treatment 
experience. 
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5.8 Transmitted drug resistance in Estonia  
is low but increasing 
As presented above (see 5.5) no primary DRMs in PR-RT were identified in 
viruses sampled in 2005-2006. However, two years later in 2008 among newly 
diagnosed HIV-1 positive subjects the prevalence of primary DRM was found 
in 8 out of 145 subjects (5.5%; 95% CI 1.8 – 9.24). The dual class resistance 
was detected in three cases (2.1%; 95% CI 0 – 4.39). This indicates that the 
prevalence of TDR mutations is rapidly increasing, especially in the light of 
corresponding figures from Western-Europe as well as other developed 
countries where the prevalence of TDR has been rather stable (Wensing, van de 
Vijver et al. 2005; Vercauteren, Wensing et al. 2009).  
However, despite of the rapid increase of TDR in Estonia its level at 5.5% is 
still lower than in developed countries – about 9% in Western-Europe and 15–
20% in North-America (Wensing, van de Vijver et al. 2005; Booth, Garcia-Diaz 
et al. 2007; Hurt, McCoy et al. 2009; Vercauteren, Wensing et al. 2009). This 
situation is most likely triggered by different history of ARV use in the Western 
world in comparison to Eastern-Europe including Estonia. Firstly, the Estonian 
CRF06_cpx viruses have never been exposed to mono- or dual therapy which 
was the leading cause of emerging TDR in Western-European subtype B 
epidemics. Secondly, the HIV-1 subtype B strains which circulated in Estonia at 
the time of mono- and dual therapy are not epidemiologically linked to viruses 
causing current concentrated HIV-1 epidemic among IVDU (Ustina, Zilmer et 
al. 2001). 
Comparing TDR mutations figures of other regions where the CRF06_cpx 
viruses spread (e.g. Burkina Faso, Mali) it appears that their level of TDR is 
higher than in Estonia (about 11%) and this is despite of restricted use of ARVs 
and short duration of HAART in these regions (Tebit, Sangare et al. 2009). This 
suggests that not only the availability of ARV agents, but also socio-economic 
and demographic factors are likely to contribute to the development of ARV 
resistance (Vergne, Diagbouga et al. 2006; Derache, Traore et al. 2007).  
 Amongst other Eastern-European countries the prospectively and systema-
tically collected data on TDR are available only about Poland and Hungary. The 
TDR mutations rates in these countries are 4-14% and follow Western-
European rather than Eastern-European trends. This is not surprising as these 
countries are not affected by the so called new Eastern-European type IVDU 
HIV-1 epidemics (Kanizsai, Ghidan et al. 2010; Stanczak, Stanczak et al. 2011).  
Some information about TDR in Eastern-European IVDUs epidemic has 
been published in Latvia indicating that the TDR ranges from 3.4% to 7% and 
resembles very much the situation in Estonia (Kolupajeva, Aldins et al. 2008; 
Balode, Westman et al. 2010). In other Eastern-European countries affected by 
the IVDUs epidemics the monitoring of TDR has been sporadic and thus does 
not allow to follow time trends or draw conclusions on its rates. The studies are 
usually very small in size and the level of TDR is 0-4% (Zarandia, Tsertsvadze 
et al. 2006; Vinogradova, Gafurova et al. 2010).  
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When analysing rapid increase of TDR in Estonia between 2005-2006 and 
2008 one should bear in mind the differences in study designs (TN PR-RT and 
TDR study, Table 2). The TN PR-RT study was cross-sectional and consisted of 
patients diagnosed HIV positive between 2000 and 2005, whereas the TDR 
study conducted in 2008 invloved only newly diagnosed patients. The fact that 
the TN PR-RT study contains mostly chronically infected subjects may lead to 
the underestimation of TDR in this population, because viruses might lose their 
DRMs in actively replicating viral population without the lasting ARV pressure.  
 
5.8.1 The distribution of transmitted drug resistance mutations 
 
Among TDR populations NRTI, NNRTI and PI resistance mutations were 
found in similar frequency – in 4 (2.8%), 3 (2.1%), 4 (2.8%) cases, respectively.  
The most commonly observed mutations were RT K103N, PR M46I and PR 
L90M (each seen in three cases, 2.1%) and RT M41L and PR I85V (both seen 
in two viruses, 1.3%). The NRTI mutations M184V, M184I, T215C, T215D 
and NNRTI mutation P225H were all seen in a single case. Other substitutions 
associated with DR like the RT V108I and V179E were described each in two 
viral strains. As HIV-1 is a quickly mutating virus, not all described DRMs 
from these were presented in population as pure aa. Polymorphic positions from 
aforementioned mutations located in the RT positions K103KN and T215DN 
and PR positions T74ST and L90LM, each found in one case.  
The relatively equal distribution of different DRM classes as well as low 
proportion of TAMs (M41L, T215C and T215D), seen in 4 out of 18 described 
DRMs only, refers to a modern pattern of DRMs and is similar to the HIV-1 
DRMs accumulating in developed countries today (Bartmeyer, Kuecherer et al. 
2010). These findings are not surprising as in Estonia large scale ARV therapy 
started after the introduction of HAART and only a tiny minority of HIV 
positive subjects have received mono- and/or dual therapy, but this happened 
before year 2000 when most inpatients were infected with subtype B viruses 
(Laisaar, Avi et al. 2011). Furthermore the pattern of TDR mutations also 
corresponds to the profile of ARV agents used in Estonia during last years (see 
5.9).   
 
5.8.2 The clusters of transmitted drug resistance mutations 
 
According to the analysis of the phylogenetic relations of TDR mutations 
possessing viruses no monophyletic clusters carrying the same pattern of TDR 
mutations were found (Figure 1 in Article 3). This was actually expected as the 
DRM carrying viruses have been circulating in the Estonian population for a 
relatively short period of time.  
The only possible TDR mutations transmission cluster might have been  
formed by two subtype B viruses as they possessed nearly identical DRM 
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patterns (PR M46I, I85V, L90M, RT M41L, T215C and PR M46I, I85V, 
L90M, RT M41L, T215DN) (Figure 1 in Article 3). However, the low number 
of the Estonian subtype B viruses in the current phylogenetic analysis does not 
allow to confirm the existence of significance of this cluster.   
Corresponding studies in Western-Europe have described that 20% of TDR 
mutations carring viruses cluster to TDR clusters (Brenner, Roger et al. 2008; 
Hughes, Fearnhill et al. 2009).  
 
 
5.9 CRF06_cpx drug resistance mutations  
in treatment experienced population 
 
During 2001 to 2008 the ARV consumption has constantly risen from 0.077 DDD 
/1000/per day in 2001 to 1.481 DDD in 2008 (Figure 7). The rate of subjects 
receiving ARV therapy has also increased (from 1.7% of all HIV positive subjects 
in 2001 to 14.9% in 2008) (Estonian Health Board, Tallinn, 2010 (cited 2010 
February 16). Accessed at www.terviseamet.ee). This reflects the situation 
characteristic to new HIV-1 epidemics. The most commonly used ARV agents in 
2008 were 3TC (0.565 DDD), ddI (0.311 DDD), ZDV (0.217 DDD), EFV (DDD 
0.196) and LPV/r (0.147 DDD). It is in accordance with Estonian and inter-
national HIV treatment guidelines (aidsinfo.nih.gov). 
 
 
 
 
Figure 7. The consumption of ARV agents (dotted line) and percentage of HIV positive 
persons on HAART (solid line) in Estonia 2001–2008 as reported by the Estonian State 
Agency of Medicines, Tartu 2010 (cited 2010 February 16) Accessed at www.sam.ee) 
and Estonian Health Board, Tallinn, 2010 (cited 2010 February 16). Accessed at 
www.terviseamet.ee) 
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Between September 2006 and November 2010 83 treatment experienced 
patients with ARV failure have been tested for genotypic HIV-1 drug resistance 
(78 of them have failed their first HAART regimen) in the Institute of 
Microbiology of University of Tartu. The viral genomic RNA was successfully 
sequenced in PR and RT regions in total of 59 cases. At least one DRM was 
detected in 34 (58%) cases – NRTI, NNRTI and PI resistance was detected in 
23 (39%), 31(53%) and 3(5%) cases, respectively. The predominant NRTI 
mutations were M184V, L74V, L74I, K70E and K219E found in 22, 8, 3, 2 and 
2 cases, respectively (Table 6). NNRTI DRMs were K103N, Y188L, L100I and 
P225H presented in 28, 4, 3 and 3 cases, respectively. In PI treated population 
the most frequent PI DRM was V82A in 2 cases. 
 
 
Table 6. The distribution of DRMs in TE PR-RT population.  
 
Class Mutation Abs. number % 
NRTI M184V 22 39 
 L74V 8 14 
 L74I 3 5 
 K70E 2 4 
 K219E 2 4 
 M41L 1 2 
 D67N 1 2 
 K70R 1 2 
 M184I 1 2 
 T215F 1 2 
NNRTI K103N 28 49 
 Y188L 4 7 
 L100I 3 5 
 P225H 3 5 
 K101E 1 2 
 K103S 1 2 
 V106M 1 2 
 G190A 1 2 
 G190S 1 2 
PI V82A 2 4 
 M46I 1 2 
 I47V 1 2 
 F53L 1 2 
 I54V 1 2 
 L90M 1 2 
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As expected the most common mutations (M184IV, L74IV and K103N) confer 
resistance to ARV drugs with low-genetic barrier  3TC, ZDV and NVP. These 
three mutations have been widely spread also among the other B and non-B 
subtypes in NRTI and/or NNRTI treated persons (hivdb.stanford.edu). 
The diversity of the DRM in Estonian TE patients, however, is narrower 
than  that in the Western- and Northern-Europe (Wensing, van de Vijver et al. 
2005; Vercauteren, Wensing et al. 2009). The most likely reason is the fact that 
majority of HAART failing patients have failed only their first treatment 
regimen, and due to the limited use of mono- and dual therapy in 1990s the 
number of patients with multiresistant HIV-1 strains is very low. In contrast, the 
CRF06_cpx viruses in other countries (Burkina Faso and Mali) possess more 
diverse DRM profile, including high prevalence of TAMs which in turn 
suggests higher proportion of subjects on suboptimal therapy or wider use of 
thymidine analogues (Tebit, Sangare et al. 2008).   
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6. GENERAL DISCUSSION 
 
The current study investigating the genetic structure of Estonian HIV-1 viruses 
has provided one of the most comprehensive molecular insights into the new 
HIV-1 epidemics in Eastern-Europe, the area poorly characterized thus far. In 
contrast to Western-European predominantly homo- and heterosexually trans-
mitted infections the new epidemics, including the Estonian one, mostly include 
young male IVDUs and are usually caused by very homogeneous monophyletic 
non-B subtype viruses (Bobkov, Cheingsong-Popov et al. 1997; Zetterberg, 
Ustina et al. 2004).  
The distribution of HIV-1 subtypes in various parts of the world is likely the 
most widely studied area in the molecular epidemiology of infectious diseases. 
The main reason for such an intense investigation is the urgent need to improve 
prevention including development of vaccines. This requires comprehensive 
knowledge of molecular diversity of viral subtypes and their associations with 
other epidemiological factors (e.g. superinfections with other HIV-1 strains, co-
infections with other viruses like HCV, HBV, HSV etc). The importance of 
HIV-1 subtypes lies also in their impact  on transmissibility, disease progres-
sion, and the response to ARV therapy (Geretti 2006).  
The current study demonstrated that throughout the concentrated Estonian 
HIV-1 epidemic the subtype distribution has undergone only minor changes; the 
CRF06_cpx viruses have predominated since year 2000 (Zetterberg, Ustina et 
al. 2004; Adojaan, Kivisild et al. 2005). These findings are concordant with 
those in other Eastern-European IVDU HIV-1 epidemics that have de-
monstrated a stable distribution of subtype A1 viruses (Rumyantseva, Olk-
hovskiy et al. 2009).  
Interstingly during last 10 years the spread of CRF06_cpx viruses has been 
restricted mainly to Estonia and only single cases have been described in  
neighboring countries in Latvia, Sweden and St. Petersburg area of Russia 
(Skar, Sylvan et al. 2008; Masharsky, Dukhovlinova et al. 2010). On the same 
token the low prevalence of subtype A1 in Estonia is also surprising as this 
strain has caused massive outbreaks in many former Soviet Union countries that 
became affected by the IVDU epidemics just a year before the Estonian 
CRF06_cpx outbreak (Rumyantseva, Olkhovskiy et al. 2009).  
It is noteworthy to mention that despite of very high incidence of HIV-1 (27.8 
per 100,000 persons) the epidemic has not spread across the country and is still 
restricted to the North and North-East Estonia. However the spread from IVDU 
male to heterosexually infected women has occurred (Estonian Health Board, 
Tallinn, 2010 (cited 2010 February 16). Accessed at  www.terviseamet.ee). 
Therefore one could hypothesize that HIV-1 strains that once have infected the 
subjects, could saturate a certain population of IVDUs and thus possess a 
sufficient protection against other HIV-1 strains.  
Another feature characteristic to new IVDU epidemics is the monophyletic 
virus population as shown in the current study as well as in other Eastern-
European countries and IVDU populations (Tovanabutra, Beyrer et al. 2004; 
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Thomson, de Parga et al. 2007). The spread of monophyletic and homogeneous 
viral strains among this risk group is potentially facilitated by several factors. 
Firstly, the IVDU transmission lacks the mucosal barrier and therefore enables 
virus to replicate for relatively long periods without a specific immune 
response. Secondly, many Estonian IVDUs abuse opiates, which at least in in 
vitro studies have been shown to be inducers of co-receptor CCR5 expression, 
therefore creating improved opportunities for the viral amplification (Guo, Li et 
al. 2002; Talu, Rajaleid et al. 2010). In clinical context such homogeneous viral 
epidemics may mean similar disease progression and response to ARV therapy. 
On the other hand, the latter one could also explain the homogeneous DRM 
pattern in TE population in Estonia described by us.  
An important practical finding of the current study is that the Estonian 
CRF06_cpx or its recombinants with subtype A1 viruses do not possess 
naturally occurring primary or accessory DRMs in the PR, RT or IN region 
indicating that all circulating viruses should be susceptible to currently available 
ARV agents. For the practicing physicians this means that all first line ARV 
regimens suggested by the international HIV treatment guidelines including 
older agents are potentially appropriate choice for the treatment of HIV-1 
infection in Estonia. However, so far no clinical trials have been conducted to 
prove that this is true in clinical practice. The absence of naturally occurring 
DRMs is also characteristic to all other HIV-1 group M subtypes (including 
subtype B) (Kantor 2005, Kantor 2006).   
The current study was one of the few that genotyped the PR region and the 
first one genotyping the IN region in a rare HIV-1 clade like CRF06_cpx. A 
high frequency of natural polymorphisms in PR and IN region was de-
monstrated affirming once again that non-B subtype viruses are rich in poly-
morphism in PR and IN region (Rhee, Gonzales et al. 2003; Rhee, Liu et al. 
2008). The clinical relevance of these polymorphisms is still unclear. One could 
speculate that they facilitate resistance development to ARV agents. Although 
studies on this are still limited the ones that have pooled many different non-B 
subtype viruses indicate that the subtype does not play a role in response to 
HAART. However, more recently the number of patients infected and treated 
with the non-B subtypes has risen worldwide. As a result studies demonstrating 
subtype specific pathways in DRM development and even subtype dependent 
efficiency of ART regimens have been published (Perno, Cozzi-Lepri et al. 
2001; Brenner, Turner et al. 2003; Abecasis, Deforche et al. 2005; Kantor, 
Katzenstein et al. 2005). There is clearly a need for appropriately designed 
studies, especially in areas of new IVDUs epidemics to resolve the issue of 
influence of subtypes on the treatment response. 
We also demonstrated the rapid rise of TDR from 0% to 5% in two years 
(2006-2008) among Estonian treatment naïve HIV-1 subjects. Although such 
rapid rise is of concern it is still about two times lower than recently reported  in 
the homo- and heterosexually transmitted Western-European and North-
American epidemics where the rates have  stabilized to about 9% or even show 
decreasing trends in some regions (Wensing, van de Vijver et al. 2005; 
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Vercauteren, Wensing et al. 2009). The initial absence of TDR in Estonia was 
expected as majority of the Estonian HIV-1 patients have received HAART 
instead of mono- or dual therapy; the latter being the main cause of the rapid 
increase of TDR in Western-Europe in 1980-90s (Schuurman, Nijhuis et al. 
1995; Wensing, van de Vijver et al. 2005; Vercauteren, Wensing et al. 2009). 
Furthermore, although a population of mainly homosexual subjects undergoing 
mono- or dual therapy in 1990s existed in Estonia, it was very small and had  
probably no epidemiological links to the IVDUs forming the predominant 
population in the current concentrated epidemic (Ustina, Zilmer et al. 2001). 
The rapid increase in TDR by 2008 is more difficult to explain. One could 
speculate that the potential reasons are a dramatic scaling up of the HAART 
(seven fold from 2004 to 2007) and poor adherence of ARVs likely to occur in 
the IVDUs population. The wide fluctuations of TDR levels have been 
suggested among IVDUs in the territory of new Eastern-European epidemics, 
however, data are still very limited (Vazquez de Parga, Rakhmanova et al. 
2005; Zarandia, Tsertsvadze et al. 2006; Vinogradova, Gafurova et al. 2010).  
Pointing out the main limitations of the current study one should notice the 
cross-sectional study designs and the inability of Sanger sequencing to detect 
DRMs in minority viral quasi-species. More recently new and very sensitive 
technologies like real-time PCR or deep and ultra-deep sequencing have been 
developed and introduced; they have a potential to describe additional minority 
DRMs (Metzner, Leemann et al. 2011; Mild, Hedskog et al. 2011). The second 
limiting factor is the underestimation of TDR mutations due to the studied 
population which consisted of newly diagnosed rather than newly infected 
subjects. Some US and European studies have noted that newly diagnosed 
persons might posses lower level of TDR because of longer replication time 
without the ARV pressure, which leads to the disappearance of mutation 
possessing viruses from the actively replicating population (Weinstock, Zaidi et 
al. 2004; Wensing, van de Vijver et al. 2005). Thirdly, the current study could 
not report some DRM mutations which recently have been described to accu-
mulate in viral gag cleavage sites or RNase H region, because these mutation 
locate in viral genomic region that remained out of the scope of the conducted 
analyses (Weinstock, Zaidi et al. 2004; Knops, Kemper et al. 2010; Michels, 
Staszewski et al. 2010).  
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7. CONCLUSIONS 
 
 The HIV-1 subtype distribution in Estonia after the commencement of the 
concentrated outbreak in early 2000s has remained stable at least until 
2008. The vast majority of viruses according to the sequenced regions (V3, 
PR, RT and IN) belong to the monophyletic CRF06_cpx cluster. In fewer 
cases the CRF06_cpx has formed local recombinants mainly with the 
Eastern-European subtype A1 viruses. These recombinant sequences were 
found in all genomic regions except the V3. At the same time the subtype 
B viruses, widely spread in Western-Europe and subtype A1 circulating in 
Latvia and Russia were found only in single cases. All this suggests that 
the Estonian HIV-1 epidemic has developed independently and even now 
is minimally influenced by foreign or neighboring HIV-1 epidemics.   
 Estonian CRF06_cpx and its recombinant viruses do not possess any 
naturally occurring PR, RT and IN DRMs suggesting their similarity to 
other HIV-1 group M subtypes and CRFs. In practical terms this means 
that viruses circulating in Estonia should be susceptible to all available 
ARV agents. Thus the ARV treatment guidelines developed mainly for 
subtype B viruses are applicable in the Estonian settings. However, similar 
to other non-subtype B viruses almost all Estonian CRF06_cpx and 
recombinant viruses possess numerous DR associated natural poly-
morphisms in PR and IN region. The clinical relevance of these poly-
morphisms is still largely unknown. Recent studies have shown their 
association with the development of subtype specific DRM pattern in 
different HIV-1 subtypes. Thus, in  the circumstances of increasing use of 
ARV therapy clinical studies to estimate the influence of natural poly-
morphisms or subtype on the response to ARV therapy are urgently 
needed, especially in case of new epidemics of Eastern-Europe.  
 There is no correlation between RT region DRMs and IN region poly-
morphisms among Estonian TE and DRM possessing HIV-1 CRF06_cpx 
viruses. 
 The level of TDR in 2008 in Estonia is still low (5.5%). However, after 
scaling up ARV treatment a rapid increase has been observed. All this 
indicates that there is a need to monitor patients for DRM prior the 
beginning of ARV therapy. In any case a plasma sample should be 
collected for future DR testing. 
 The pattern of DRMs in HIV-1 CRF06_cpx among TE patients failing 
ARV therapy is largely similar to that seen in Western-Europe among 
subtype B viruses. The predominant presentation of NNRTI and NRTI 
DRMs reflects rather the character of consumed ARV agents than the 
specifics of viral subtype.     
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8. SUMMARY IN ESTONIAN 
 
Eestis ringlevate HIV-1 CRF06_cpx ja tema  
rekombinantsete viiruste looduslikud polümorfismid ja  
ülekanduv ravimresistentsus 
 
Viimastel kümnenditel on HIV-1 infektsioon muutunud maailma üheks olulise-
maks nakkushaiguseks. 2009 aastal oli maailmas umbes 31-35 miljonit HIV  
positiivset, AIDS-i suri 1,8 miljonit inimest ning uusi nakkusjuhte oli 2,6 mil-
jonit. 
Geneetilise mitmekesisuse alusel jagatakse HIV-1 viirused kolme suurde 
gruppi, millest ülemaailmset epideemiat põhjustavad peamiselt M-grupi viiru-
sed. Need jagunevad omakorda 9 subtüübiks (A, B, C, D, F, G, H, K, J) ning 
mitmekümneks nendevaheliseks rekombinantseks vormiks (CRF01_AE, 
CRF02_AG jne.). 
Alates 1995. aastast on HIV-1 vastases ravis kasutusel HAART (highly 
active antiretroviral therapy) – kombinatsioon vähemalt kolmest retroviiruse 
vastasest ravimist. Taolise ravi kasutuselevõtuga kaasnes põhimõtteline 
murrang – raskest surmaga lõppevast tõvest on saanud krooniline suhteliselt 
kõrget elukvaliteeti lubav haigus. Paraku on HAARTiga eotud ka mitmed 
probleemid, sealhulgas ravimresistentsuse teke. Seda tingib viiruse vigaderohke 
replikatsiooniprotsess, mis ravirežiimi rikkumise korral põhjustab kiire ravim-
resistentsusmutatsioonide (RRM) ilmumise.   
HIV-1 RRM-id võib jagada primaarseteks ehk otseselt ravimresistentsust 
tekitavateks ning sekundaarseteks ehk RRM kandvate viiruste replikatsiooni-
võimet taastavateks mutatsioonideks. Viimased võivad esineda erinevatel HIV-
1 subtüüpidel ka looduslike polümorfismidena eriti viiruse proteaasi (PR) ja 
integraasi (IN) piirkonnas. Siiani on üksikud uuringud näidanud, et need 
polümorfismid ei mõjuta otseselt ARV-ravi efektiivsust, kuigi neil võib olla 
mõju ARV käigus kujuneval RRM mustrile.  
Üheks oluliseks ARV-ravi edukust mõjutavaks teguriks on ülekanduv ravim-
resistentsus. See omandatakse koos ülekanduva viirusega varem ravi saanud 
patsientidelt. Paljudes, eriti pikaaegse ARV-ravi ajalooga riikides (nt USA) 
ulatub selle tase kuni 20 protsendini, Euroopas on see aga viimastel aastatel 
püsinud 9 protsendi piires.    
Eestis puhkes konsentreeritud HIV-1 epideemia 2000. aastal, mis viis Eesti 
nii HIV-1 uute juhtude kui ka üldise levimuse osas Euroopa juhtivate riikide 
hulka. Oma iseloomult kuulub Eesti epideemia nn Ida-Euroopa uut tüüpi HIV-1 
epideemia piirkonda, mida iseloomustab väga kõrge HIV-1 ja HCV levimus 
peamiselt noorte meessoost süstivate narkomaanide hulgas. Nakkust põhjus-
tavad seda tüüpi epideemiates molekulaarselt väga sarnased monofüleetilist 
päritolu HIV-1 tüved. Peaaegu kogu Ida-Euroopas on selleks subtüüpi A1 
kuuluv tüvi, vähesel määral aga  ka CRF03_AB. Eesti on siinkohal erandlik, 
kuna nakkust põhjustab peamiselt  HIV-1 CRF06_cpx viirus. Nimetatud 
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rekombinantse vormi laiemat levikut on seni kirjeldatud vaid mõnes Lääne-
Aafrika riigis.  
HIV-1 viiruse looduslikke polümorfismide, RRM-de ning ülekanduva 
ravimresistentsuse levikut on Ida-Euroopas siiani uuritud suhteliselt vähe. 
Üksikud ilmunud tööd käsitlevad sageli väikesi populatsioone ning läbilõike 
uuringutena suudavad anda infot vaid piiratud aastate kohta. Enne käesoleva töö 
läbiviimist polnud avaldatud ühtegi uuringut Eestis levinud HIV-1 CRF06_cpx 
viiruste ravimresistentsusega seotud polümorfismide, RRM-de ning ülekanduva 
ravimresistentsuse kohta.  
 
 
Uurimistöö eesmärgid 
 
Töö üldine eesmärk oli kirjeldada Eestis ringlevate HIV-1 viiruste ravim-
resistentsuse mustrit nii ARV-ravi mitte saanud kui ka saanud isikutel.  
Uuringu alaeesmärgid olid:  
 Kirjeldada Eestis ringlevate viiruse V3, PR, RT ja IN genoomsete piir-
kondade genotüüpe aastatel 2005 kuni 2006 ja 2008  
 Kirjeldada ravinaiivsete viiruste PR, RT ja IN genoomsete piirkondade 
looduslikke polümorfisme Eestis ringlevatel HIV-1 CRF06_cpx ja tema 
järgmise põlvkonna rekombinantidel 
 Kirjeldada seoseid Eestis ringlevate HIV-1 CRF06_cpx ja tema järgmise 
põlvkonna rekombinantsete viiruste RT regiooni primaarsete RRM-de ja IN 
regiooni polümorfismide vahel  
 Võrrelda HIV-1 ülekanduvat ravimresistentsust 2005-2006 ja 2008 aastal  
 Kirjeldada primaarseid RRM Eestis ringlevatel HIV-1 CRF06_cpx ja tema 
järgmise põlvkonna rekombinantidel ravi saanud patsientidel.  
 
 
Uuritavad ja metoodika 
 
Uuring viidi läbi järgnevates osades:  
 Esimene uuring määras HIV-1 viiruse PR, RT polümorfisme. Uuritavateks 
olid 2005–2006 aastal Ida-Viru Keskhaigla ning Tartu vanglas HIV-
positiivsed ravinaiivsed patsiendid. Uuritavate demograafilised näitajad olid 
üldjoontes sarnased Eesti HIV-1 positiivsete vastavate näitajatega (65% olid 
süstivad narkomaanid, 70% mehed ja keskmine vanus 27 aastat). 
 Teine uuring keskendus IN piirkonna polümorfismide ja RRM-ide uuri-
misele. Uuritav populatsioon koosnes valdavalt eelmainitud populatsiooni 
patsientidest.  
 Kolmas uuring vaatles RT piirkonna RRM-de mõju IN piirkonna polü-
morfismidele aastatel 20062007 Tartu Ülikooli Mikrobioloogia Instituuti 
saadetud ARV ravi läbikukkunute viirustel. 
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 Neljanda uuringu populatsiooni moodustasid ülekanduva ravimresistentsuse 
määramiseks 2008. aastal HIV positiivseks diagnoositud ravinaiivsed isikud.  
 Viienda uuringu populatsiooniks olid HIV-1 CRF06_cpx viiruste RRM 
mustri uurimiseks aastatel 20062010 Tartu Ülikooli Mikrobioloogia 
Instituuti saadetud ARV ravi läbikukkunute koeproovid. 
Kõikides uuringutes sekveneeriti patsientide vereplasmast eraldatud viiruse 
genoomne RNA, mis oli konverteeritud pöörd-transkriptsiooniga cDNA-ks ja 
paljundatud nested-PCR-iga. Saadud järjestusted assambleeriti kontiigideks, 
mida kasutati fülogeneetilisteks analüüsideks, rekombinatsioonide määra-
miseks, ravimresistentsusmutatsioonide ning geneetiliste polümorfismide 
detekteerimiseks.  
 
 
Peamised tulemused ja arutelu 
 
Kooskõlas varasemate Eestis läbiviidud uuringutega on alates 2000. aastast 
jäänud Eesti HIV-1 subtüübiline jaotuvus muutumatuks. Kõikides sekvenee-
ritud HIV-1 piirkondades moodustasid enamuse (umbes 85%) CRF06_cpx 
viirused, millele järgnesid (umbes 12%) Eesti kohalikku päritolu rekombi-
nantsed vormid. Üksikjuhtudel kirjeldati ka A, B, CRF02_AG ja CRF03_AB 
subtüüpidesse kuuluvaid viiruseid. Looduslikke ravimresistentsusmutatsioone 
Eestis ringlevatel viirustel ei leitud ei PR-RT ega ka IN piirkonnas. Seega 
peaksid Eestis levivad HIV-1 viirused olema tundlikud kõigile olemasolevatele 
ARV ravimitele. Seevastu leidus hulgaliselt mitte-B subtüüpidele omaseid 
ARV-raviga seotud polümorfisme, millest paljud olid tugevalt konserveerunud 
ning esinesid rohkem kui 90% viirustest – PR regioonis K14R, M36I, H69K ja 
L89M ning IN regioonis V72I, L74I, V201I ja T206S. Ilmselt ei mõjuta 
nimetatud polümorfismid HAART efektiivsust otseselt, küll aga võivad nad 
põhjustada subtüübi spetsiifilist RRM kujunemist.   
2008. aastal läbi viidud uuring näitas värskelt HIV-1 positiivseks diagnoo-
situte ravinaiivsete isikute hulgas ravimresistentsuse tõusu 5%-ni. Mitmetes 
HIV-1 ravijuhistes on nimetatud tase määraks, millest alates soovitatakse läbi 
viia ravieelset genotüüpilist HIV-1 ravimresistentsustesti. Leitud ülekanduvatest 
RRM-idest olid suhteliselt võrdselt levinud kõik peamised ARV ravimklasside 
mutatsioonid (NRTI – 2,8%, NNRTI – 2,1%, PI – 2,8%). Kuigi Eesti ülekan-
dunud ravimresistentsus jääb hetkel veel madalamaks kui Euroopa vastav 
näitaja, ei pruugi edasine olukord taolisena püsida. Sellele viitab Eesti HIV 
positiivsete isikute erinev demograafiline stuktuur – erinevalt Lääne-Euroopa 
HIV positiivsetest on nad reeglina noored mehed, nakatunud intravenoosselt 
ning nad pole kunagi saanud HIV-1 vastast monoteraapiat, mis on olnud Lääne-
Euroopas üks põhilisi ülekanduva ravimresistentsuse põhjustajaid. Samuti võib 
edasisele ülekanduvale ravimresistentsuse tõusule oma mõju avaldada ka Ida-
Euroopa HIV-1 epideemiale omane kiirelt kasvav ARV-ravimite tarvitamine ja 
süstivatele narkomaanidele omased adherentsi probleemid.  
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Töö viimases osas analüüsitud ravi saanute populatsioonis leiti RRM-d 34 
viirusel (58%). Levinumad olid NRTI mutatsioonid M184IV, L74IV, K70ERQ, 
K219E, L74I/V ja T215YF, NNRTI mutatsioonid K103N, V179E, V108I, 
K101EN ja G190AS ning PI mutatsioonid L90M, M46I, I54V ja V82SA. 
Nimetatud mutatsioonide esinemine korreleerub hästi Eestis kasutatavate 
peamiste ARV ravi režiimidega. Samuti on RRM muster suhteliselt sarnane 
teiste arenenud riikide mutatsioonide mustriga. Ainsaks oluliseks erinevuseks 
on subtüübispetsiifilise V179E suur esinemissagedus CRF06_cpx viirustel 
võrreldes subtüüp B viirusega. 
 
 
Järeldused 
 
 Eesti HIV-1 viiruse subtüübilises struktuuris on viimasel aastkümnel olnud 
stabiilselt valitsevaks tüveks CRF06_cpx ja vähesemal määral tema 
rekombinantsed vormid teiste subtüüpide, eelkõige subtüüp A1 viirustega. 
Taoline olukord viitab Eesti HIV-1 populatsiooni suhtelisele resistentsusele 
teiste naaberpiirkondades levinud subtüüpide leviku ees.  
 Eestis CRF06_cpx viirustel ei esine looduslikult RRM-e peamistes ARV 
sihtmärk regioonides (PR, RT ja IN). See näitab, et Eesti HIV-1 on tundlik 
kõikidele laiemalt levinud ARV ravimite klassidele ja et rahvusvahelised 
HIV-1 ravijuhised sobivad ka Eesti HIV-1 infektsiooni raviks.  
 Eestis levivatel HIV-1 viirustel leiti PR ja IN regioonis mitmeid kõrge 
esinemissagedusega ARV-raviga seotud looduslikke polümorfisme. Nende 
otsene mõju ravi edukusele pole veel teada ning vajab edasisi kliinilisi 
uuringuid.  
 2008. aastal HIV positiivseks diagnoositute hulgas leiti, et ülekandunud 
ravimresistentsus on tõusnud 5%-ni. Nimetatud tase on piiriks, millest alates 
on rahvusvahelistes ravijuhistes soovituslikuks ravieelne HIV-1 geno-
tüüpilisustestide läbiviimine.  
 Ebaõnnestunult ravitud patsientide viiruste sagedasemate RRM jaotus on  
CRF06_cpx viiruste korral sarnane subtüüp B viirustega. Nimetatu viitab, et 
kuigi CRF06_cpx viirused vastavad ARV-ravile sarnaselt subtüüp B viiruste-
ga, võib neil esineda subtüübispetsiifilisi ravimresistentsusmutatsioone ning 
sellest lähtuvad ka subtüübispetsiifilised eripärad ARV-ravile allumises. 
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